Select Comfort Corporation (SCSS) Prices Common Stock

Dec. 8, 2009 (Business Wire) — Select Comfort Corporation (NASDAQ: SCSS), today announced the pricing of its previously announced underwritten public offering of 3.8 million shares of its common stock at a public-offering price of $4.75 per share. Piper Jaffray is acting as the sole manager for the public offering.

The public offering will result in gross proceeds of $18,050,000 and, after deducting underwriting discounts and commissions, net proceeds of $16,967,000. Additional public offering expenses are expected to be approximately $500,000. If Sterling Partners exercises its preemptive rights to maintain its percentage ownership at approximately 9.0 percent, an additional 341,254 shares of common stock would be issued upon the same terms as the issuance of shares in the public offering. The public offering is subject to customary closing conditions and is expected to close Dec. 11, 2009.

The company plans to use the proceeds of the public offering to improve working capital and pay down debt. Under the terms of the company’s amended and restated credit agreement dated Nov. 13, 2009, the aggregate amount available under the credit facility at closing will be $40 million. The proceeds from this public offering are expected to fulfill the company’s obligation under the credit agreement to issue additional equity.

The public offering is being made pursuant to an effective shelf registration statement. Copies of the prospectus supplement and accompanying base prospectus relating to the offering may be obtained from the Securities and Exchange Commission (SEC) at www.sec.gov, or by contacting Piper Jaffray & Co., by mail at 800 Nicollet Mall, Suite 800, Minneapolis, MN, 55402; or by phone at (800) 747-3924.

This news release does not constitute an offer to sell, or the solicitation of an offer to buy shares of common stock. Select Comfort also will not sell any of the common stock and has been advised by Piper Jaffray that it and its affiliates will not sell any of the common stock in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification of the shares under the securities laws of any such state or jurisdiction.

About Select Comfort Corporation

Founded more than 20 years ago and based in Minneapolis, Select Comfort Corporation designs, manufactures, markets and supports a line of adjustable-firmness mattresses featuring air-chamber technology, branded the Sleep Number^® bed, as well as foundations and bedding accessories. SELECT COMFORT^® products are sold through its approximately 400 company-owned stores located across the United States; select bedding retailers; direct marketing operations; and online at www.sleepnumber.com.

Forward-Looking Statements

Statements used in this news release relating to future plans, events, financial results or performance are forward-looking statements subject to certain risks and uncertainties including, among others, such factors as our ability to fund our operations through cash flow from operations or availability under our bank line of credit or other sources, market, economic or other factors that may cause us to change from our planned use of proceeds, and the cost of credit or other capital resources necessary to finance operations; the risk of non-compliance with financial covenants under our bank line of credit; the potential need to obtain additional capital through the issuance of debt or equity securities, which may significantly increase our costs or dilute our existing shareholders, and the risk that we may not be successful in obtaining additional capital that may be needed; current general and industry economic trends; consumer confidence; the effectiveness of our marketing messages; the efficiency of our advertising and promotional efforts; consumer acceptance of our products, product quality, innovation and brand image; availability of attractive and cost-effective consumer credit options; execution of our retail store distribution strategy, including our ability to cost-effectively close under-performing store locations; our dependence on significant suppliers, and our ability to maintain relationships with key suppliers, including several sole-source suppliers; the vulnerability of key suppliers to recessionary pressures, labor negotiations, liquidity concerns or other factors; rising commodity costs and other inflationary pressures; industry competition; our ability to continue to improve our product line; warranty expenses; risks of pending and potentially unforeseen litigation; increasing government regulations, including new flammability standards for the bedding industry and new safety standards for consumer products, which have or will add product cost pressures and have or will require implementation of systems and manufacturing process changes to ensure compliance; the adequacy of our management information systems to meet the evolving needs of our business and evolving regulatory standards applicable to data privacy and security; our ability to attract and retain senior leadership and other key employees, including qualified sales professionals; and uncertainties arising from global events, such as terrorist attacks or a pandemic outbreak, or the threat of such events. Additional information concerning these and other risks and uncertainties is contained in our filings with the SEC, including our Annual Report on Form 10-K, and other periodic reports filed with the SEC. The company has no obligation to publicly update or revise any of the forward-looking statements in this news release.

QuadraMed (QDHC) Announces Agreement to be Acquired by Francisco Partners

Dec. 8, 2009 (Business Wire) — QuadraMed^® Corporation (NASDAQ:QDHC), a leading provider of healthcare information technologies and services that help turn quality care into positive financial outcomes, announced that it has entered into a definitive merger agreement to be acquired by Francisco Partners, one of the world’s largest technology-focused private equity firms.

Under the terms of the agreement Francisco Partners has agreed to acquire all of the outstanding shares of QuadraMed’s common stock for $8.50 per share in cash and all of the outstanding shares of QuadraMed’s Series A Cumulative Mandatory Convertible Preferred Stock for $13.7097 per share in cash. The per-share consideration to the Series A Preferred Stock represents the common-equivalent consideration for such Series A Preferred Stock based on its current conversion ratio. The all-cash transaction is valued at approximately $126 million.

The proposed purchase price per share of common stock represents a premium of approximately 32.6% to the closing share price of QuadraMed’s common stock on December 7, 2009, the last trading day prior to the public announcement of the transaction, a premium of approximately 33.3% to the 30-day trailing average closing price of QuadraMed’s common stock, and a premium of approximately 7.1% to the 52-week-high closing price of QuadraMed’s common stock.

Following the unanimous recommendation of a special committee comprised entirely of independent directors, QuadraMed’s Board of Directors approved the merger agreement and has recommended that QuadraMed’s stockholders vote to approve the merger. Piper Jaffray & Co. has acted as exclusive financial advisor and delivered a fairness opinion to the Special Committee and to the Board of Directors.

“After a thorough and careful review of the strategic alternatives available to us, QuadraMed’s special committee and Board of Directors have concluded that this transaction represents the best option to maximize value for our shareholders. The Board believes that this transaction is in the best interest of our shareholders, and is also beneficial to our customers and partners,” said James E. Peebles, Chairman of QuadraMed’s Board of Directors. “QuadraMed has a proven track record of providing software and services that help healthcare organizations turn quality care into positive financial results. Francisco Partners is a leading private equity firm that helps technology companies build on their success. I’m confident that the Company, fortified by Francisco Partners’ extensive resources, will continue to build on the impressive legacy of quality products and services offered to the healthcare industry.”

QuadraMed’s directors and executive officers and affiliates, who control approximately 8.4% in the aggregate of the outstanding common stock, have agreed to vote their shares in favor of the transaction, which is subject to customary closing conditions, including the approval of QuadraMed’s common stockholders and regulatory approval.

There is no financing condition to the transaction, but Wells Fargo Foothill, part of Wells Fargo & Company (NYSE: WFC), and Silicon Valley Bank have committed to provide debt financing for the transaction. The Company anticipates a stockholder meeting in the first quarter of 2010, with closing to follow shortly thereafter. QuadraMed plans to maintain its Reston, Virginia headquarters and operations at its various offices throughout the United States.

“Francisco Partners brings to QuadraMed extensive resources, expertise and a proven track record of helping healthcare technology companies sharpen their strategy and operational execution. Operating as a private company will also allow us to place more emphasis on generating long-term value for our clients with less distraction on short-term results for the public markets,” said Duncan James, QuadraMed’s president and chief executive officer.

“We look forward to working with Francisco Partners to execute our major strategic initiatives, which include helping our clients attain ARRA stimulus funds with the deployment of our award-winning Electronic Health Record solution (QCPR); assisting healthcare facilities with their transition from ICD-9 to ICD-10 code sets; and our on-going investment in the Company’s proven, Care Based Revenue Cycle solutions.”

“We are excited to become part of QuadraMed’s future success with this acquisition,” said Ezra Perlman, Partner, Francisco Partners. “We understand the critical role technology plays to drive quality care and to make healthcare more efficient. QuadraMed has a quality set of products, an extensive customer base, and a solid market position. We look forward to supporting Duncan and the Company’s management team as we go forward together to create long-term value for the Company’s customers, employees, and stakeholders.”

QuadraMed will represent Francisco Partners’ fifth separate investment in the healthcare IT industry including current portfolio companies API Healthcare, AdvancedMD Software, and Healthland, as well as former company, LYNX Medical Systems, which was acquired by Picis, Inc. in 2007.

In connection with the transaction, Piper Jaffray & Co. served as exclusive financial advisor and Crowell & Moring LLP acted as legal advisor to QuadraMed; William Blair & Company served as financial advisor and Shearman & Sterling LLP acted as legal advisor to Francisco Partners.

About QuadraMed Corporation

QuadraMed^® – (NASDAQ: QDHC) is a leading provider of healthcare technologies and services that help turn quality care into positive financial outcomes. QuadraMed provides innovative solutions that streamline processes, ensure compliance and help healthcare professionals deliver quality patient care. Behind the Company’s products and services is a staff of 600 professionals whose experience and dedication have earned QuadraMed the trust and loyalty of clients at over 2,000 healthcare provider facilities. For more information about QuadraMed, visit http://www.quadramed.com.

About Francisco Partners

With approximately $5.0 billion of committed capital and offices in San Francisco and London, Francisco Partners is one of the world’s largest technology-focused private equity funds. The firm was founded to pursue structured investments in technology companies undergoing strategic, technological, and operational inflection points. Francisco Partners targets majority and minority investments in private companies, public companies, and divisions of public companies, with transaction values ranging from $30 million to $2.0 billion. The principals of Francisco Partners have a proven track record, having invested in excess of $3.0 billion of equity capital in over 50 technology companies. For additional information, visit www.franciscopartners.com.

Cautionary Statement on Risks Associated with QuadraMed Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties. The words “believe,” “expect,” “target,” “goal,” “project,” “anticipate,” “predict,” “intend,” “plan,” “estimate,” “may,” “will,” “should,” “could” and similar expressions and their negatives are intended to identify such statements. Forward-looking statements are not guarantees of future performance, anticipated trends or growth in businesses, or other characterizations of future events or circumstances and are to be interpreted only as of the date on which they are made. QuadraMed undertakes no obligation to update or revise any forward-looking statement. You should not place undue reliance on these forward-looking statements. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including the risks faced by QuadraMed described in documents filed with the Securities and Exchange Commission (“SEC”) from time to time. QuadraMed’s SEC filings can be accessed through the Investor Relations section of our website, www.quadramed.com, or through the SEC’s EDGAR Database at www.sec.gov (QuadraMed has EDGAR CIK No. 0001018833).

Important Additional Information About the Transaction

In connection with the proposed transaction, QuadraMed will file with the SEC a proxy statement and relevant documents concerning the proposed transaction. QuadraMed urges investors and security holders to read the proxy statement and any other relevant documents filed with the SEC when they become available because they will contain important information about QuadraMed and the proposed transaction. QuadraMed’s SEC filings, including the proxy statement and any other transaction-related filings (when they become available), may be obtained free of charge at the SEC’s website at www.sec.gov (QuadraMed has CIK No. 0001018833), in the Investor Relations section of QuadraMed’s website, www.quadramed.com by clicking on “Investors,” then “SEC Filings,” or on the NASDAQ’s website at www.nasdaq.com. In addition, investors and security holders may obtain free copies of the documents filed with the SEC by QuadraMed by contacting QuadraMed Investor Relations at 703-709-2300, or the SEC at 800-SEC-0330 for the location of its nearest public reference room. Investors and security holders are urged to read the proxy statement and the other relevant materials when they become available before making any voting or investment decision with respect to the proposed transaction.

QuadraMed and its directors, executive officers and certain other members of its management and employees may, under SEC rules, be deemed to be participants in the solicitation of proxies from QuadraMed’s stockholders in connection with the transaction. Information regarding the interests of such directors and executive officers (which may be different than those of QuadraMed’s stockholders generally) will be included in the proxy statement relating to the proposed transaction when it becomes available. In addition, information about QuadraMed’s executive officers and directors is available in its proxy statement previously filed with the SEC on April 30, 2009. Free copies of these documents may be obtained using the contact information above.

Synta Pharmaceuticals (SNTA) Announces Encouraging Results

Dec. 7, 2009 (Business Wire) — Synta Pharmaceuticals Corp. (NASDAQ: SNTA), a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced the results of a study evaluating the activity of elesclomol against acute myeloid leukemia (AML) cell lines and primary leukemic blast cells from AML patients, presented at the Annual Meeting of the American Society of Hematology (ASH) in New Orleans.

Elesclomol is a first-in-class oxidative stress inducer that triggers apoptosis (programmed cell death) in cancer cells. In laboratory studies, elesclomol has been shown to bind copper in plasma, facilitate its uptake into cells, and enable a transition between copper oxidation states once inside cancer cells. These reactions lead ultimately to the initiation of programmed cell death via the mitochondrial apoptosis pathway.

”Oxidative stress induction is a validated therapeutic approach in hematological malignancies. The results presented at ASH provide encouraging signs of activity by elesclomol, a first-in-class oxidative stress inducer, in a range of AML cell lines,” said David Hedley, M.D., Senior Scientist, Division of Applied Molecular Oncology, Ontario Cancer Institute, and Department of Medical Oncology, Princess Margaret Hospital, Toronto. “These experiments evaluated the mechanism of action and activity of elesclomol as a single agent against cell lines representing common genetic aberrations seen in AML as well as primary blast cells from ten AML patients. Together, these results provide a strong rationale to evaluate elesclomol in this often difficult-to-treat patient population.”

“The experiments conducted at the University of Toronto showed elesclomol was highly active against AML cell lines and primary blast cells from AML patients at concentrations substantially lower than those already achieved in cancer patients in clinical trials,” said Vojo Vukovic, M.D., Ph.D., Senior Vice President and Chief Medical Officer, Synta. “Of particular interest were the ex vivo studies of primary AML blast cells from patients recently treated at Toronto, where all 10 samples of leukemic cells responded to exposure to elesclomol. These results provide a strong rationale for further exploring the potential of elesclomol in AML, a disease with high medical need and limited options for patients.”

About Acute Myeloid Leukemia

Acute Myeloid Leukemia (AML) is a cancer of the blood and bone marrow that can progress quickly if not treated. It is the most common acute leukemia affecting adults. The American Cancer Society (ACS) estimates that in 2009 about 12,810 new cases and about 9,000 deaths will occur from AML in the United States.

About Synta Pharmaceuticals

Synta Pharmaceuticals Corp. is a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to extend and enhance the lives of patients with severe medical conditions, including cancer and chronic inflammatory diseases. Synta has a unique chemical compound library, an integrated discovery engine, and a diverse pipeline of clinical- and preclinical-stage drug candidates with distinct mechanisms of action and novel chemical structures. All Synta drug candidates were invented by Synta scientists using our compound library and discovery capabilities. For more information, please visit www.syntapharma.com.

Safe Harbor Statement

This media release may contain forward-looking statements about Synta Pharmaceuticals Corp. Such forward-looking statements can be identified by the use of forward-looking terminology such as “will”, “would”, “should”, “expects”, “anticipates”, “intends”, “plans”, “believes”, “may”, “estimates”, “predicts”, “projects”, or similar expressions intended to identify forward-looking statements. Such statements, including statements relating to the timing, developments and progress of our clinical and preclinical programs, reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such forward-looking statements, including those described in “Risk Factors” of our Form 10-K for the year ended December 31, 2008 as filed with the Securities and Exchange Commission. Synta undertakes no obligation to publicly update forward-looking statements, whether because of new information, future events or otherwise, except as required by law.

China Fire (CFSG) Further Strengthens Executive Team

BEIJING, Dec. 7, 2009 (PRNewswire-Asia) — China Fire & Security Group, Inc. (Nasdaq: CFSG) (“China Fire” or the “Company”), a leading total solution provider of industrial fire protection systems in China, today announced that the Company’s Board of Directors has made several strengthening changes to the executive team, effective immediately.

To help meet China Fire’s projected rapid organic growth for the next three years and address its strategic goal of effectively consolidating the domestic fire protection industry, Mr. Gangjin Li, the Company’s founder and Chairman, has resumed his former role as China Fire’s Chief Executive Officer, responsible for the formulation and execution of corporate growth strategies. Mr. Brian Lin, the Company’s current CEO, has assumed the newly created position of Chief Financial Officer, responsible for the Company financials and capital markets. Mr. Weishe Zhang, the Company’s current Chief Technology Officer, has been appointed Vice President, responsible for strategic planning and management of marketing, technology and product development. Mr. Weigang Li continues his role as a Vice President of the Company and General Manager of China Fire’s wholly-owned subsidiary, Sureland Industrial Fire Safety Ltd (“Sureland”), responsible for the Company’s sales and Sureland’s operation management. Finally, China Fire welcomes to its executive team Mr. Min Liu, who has been appointed Director of Research and Development of China Fire as well as Sureland, responsible for designing codes and standards and innovating new customer service technologies.

“It is very exciting for me to be able to resume an active role in the company that I created. As a benefit of my considerably improved health, I feel ready and eager to help China Fire to achieve its ambitious growth goals. We now have a highly seasoned management team to help further accelerate our Company’s growth and strengthen our competitive advantages,” said Mr. Gangjin Li, Chairman and Chief Executive Officer of China Fire.

Mr. Gangjin Li, founded Sureland, China Fire’s wholly-owned subsidiary, in February 1995 and has been responsible for the strategic planning, technology development, sales and marketing of the Company. He has over 15 years’ experience in the fire protection industry in China and was named a “China Outstanding Entrepreneur” by the China Enterprise Confederation and China Enterprise Directors Association (CEC-CEDA) in 2004. Mr. Li is also an Executive Director of China Fire Protection Association (CFPA) and a member of US-based National Fire Protection Association (NFPA). He received his Master’s of Management Degree from Peking University in 1991 and Bachelor’s in Engineering from Wuhan Iron and Steel University in 1982.

Mr. Min Liu has held various positions in Sureland since 2004, including Director of the Fire Testing Center, Director of the Solutions Department, Director of the Codes & Standards Department and Director of the R&D Center. Meanwhile, he completed the layout and building of the Fire Testing Center, was in charge of the R&D of numerous fire protection solution projects and has participated in writing over ten National Codes & Standards. Mr. Liu received his Bachelor’s and Master’s degrees in Engineering Thermophysics from Tsinghua University and successively received his Ph.D. in Power Engineering & Engineering Thermophysics from Tsinghua University in 2004.

About China Fire & Security Group, Inc.

China Fire & Security Group, Inc. (NASDAQ: CFSG), through its wholly owned subsidiary, Sureland Industrial Fire Safety Limited (“Sureland”), is a leading total solution provider of industrial fire protection systems in China. Leveraging on its proprietary technologies, China Fire is engaged primarily in the design, manufacture, sales and maintenance services of a broad product portfolio including detectors, controllers, and fire extinguishers. Via its nationwide direct sales force, China Fire has built a solid client base including major companies in iron and steel, power, petrochemical and transportation industries throughout China. China Fire has a seasoned management team with strong focus on standards and technologies. Currently, China Fire has a comprehensive portfolio of patents covering fire detection, system control and fire extinguishing technologies. Founded in 1995, China Fire is headquartered in Beijing with about 600 employees in more than 30 sales and project offices throughout China. For more information about the Company, please go to http://www.chinafiresecurity.com .

Cautionary Statement Regarding Forward Looking Information

This presentation may contain forward-looking information about China Fire & Security Group, Inc. and its wholly owned subsidiary Sureland which are intended to be covered by the safe harbor for forward-looking statements provided by the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts. These statements can be identified by the use of forward-looking terminology such as “believe,” “expect,” “may,” “will,” “should,” “project,” “plan,” “seek,” “intend,” or “anticipate” or the negative thereof or comparable terminology, and include discussions of strategy, statements about industry trends and China Fire & Security Groups’ future performance, operations and products. This and other “Risk Factors” are contained in China Fire & Security Groups’ public filings with the SEC.

IXYS Corp. (IXYS) Announces Acquisition of Zilog

Dec. 7, 2009 (Business Wire) — IXYS Corporation (NASDAQ:IXYS), a market leader in power semiconductors and specialized mixed signal IC products, today announced that it has entered into a definitive agreement to acquire Zilog, Inc. (NASDAQ: ZILG), a trusted supplier of application specific, embedded microcontroller units (MCUs) that are system-on-chip (SoC) solutions for industrial and consumer markets. Under the terms of the agreement, IXYS will acquire all of Zilog’s outstanding common shares for $3.5858 per share in cash, or approximately $62.4 million. The acquisition is subject to the approval of Zilog shareholders and other customary closing conditions. The transaction is expected to be completed during the quarter ended March 31, 2010.

The combination of the two companies with complementing technologies will allow IXYS and Zilog to leverage analog power management with digital control. Zilog has a focused MCU business with technologies that will complement IXYS’ product portfolio. IXYS has a broad based and diversified range of products geared toward industrial, telecommunications, medical, automotive, alternative energy and consumer applications. By introducing MCUs that enable digital power management and embedded control, IXYS will be able to create more cost-effective system integration solutions for its diversified customer base.

“As the world migrates toward SoCs, Zilog’s core microcontroller technology along with IXYS’ core power solutions create entirely new products that will meet the needs for today and tomorrow,” said Dr. Federico Faggin, Chairman of the Board and the co-founder of Zilog, Inc.

“We are pleased with this strategic acquisition that will allow us to penetrate more applications in traditional and developing markets, leveraging both of our strengths. Digital power management is one of the fastest growing applications in the markets we serve. Zilog’s 35-year history in microcontrollers with its legendary Z80 and Z8 architectures parallels IXYS’ pioneering technologies in power MOSFETs, IGBTs and HVICs,” commented Dr. Nathan Zommer, CEO and Founder of IXYS Corporation. “With the expected rebound in MCU sales in 2010, we anticipate a growth in opportunities for refined power control in many applications; the acquisition and integration of this MCU business will strengthen our position and allow us to take advantage of these opportunities. We believe this transaction will create further value for our shareholders, employees and customers through a further expansion and diversification of our product offerings. As it is one of the pioneers of MCUs in Silicon Valley, we plan to keep the Zilog entity with its recognized and valued trademark.”

“Zilog has actively explored a broad range of strategic alternatives to enhance shareholder value. The price that IXYS is proposing to pay is a premium to our current stock price, as well as a substantial premium to the average of the prices at which we’ve traded throughout 2009,” said Darin Billerbeck, Zilog’s president and chief executive officer. “This acquisition brings liquidity to our shareholders, while increasing our financial stability in these continuing uncertain economic times.”

IXYS expects to increase its penetration in the automotive electronic and electric market by producing cost-effective integrated product offerings, including the power semiconductors, driver ICs and Zilog MCUs that are essential for automotive controls and driving displays. In IXYS’ prime industrial market, IXYS plans to deploy MCUs that are suited for motor control, power control and automation. In the telecommunications and security industries, Zilog’s MCUs complement IXYS’ ICs, which can be deployed in modems, VOIP, FIOS and automated alarm systems. For the medical market, the Zilog MCU platform complements IXYS’ power and IC products in defibrillators, imaging and diagnostics. Additionally, the recently expanded IXYS products for LED lighting and display, which require digital power control, will benefit in the market from the availability of complementary MCUs. MCU product offerings will be expanded to include low-power and sensing technologies for energy management applications, including smart lighting and intrusion detection.

In addition to expanding market opportunities, the acquisition will allow IXYS and Zilog to pool R&D resources, leverage economies of scale, reduce manufacturing costs and streamline and integrate operational and support costs. Over time, the integration is expected to result in improved financial results for the combined organization.

About IXYS Corporation

Since its founding in Silicon Valley, IXYS Corporation has continued to develop advanced technologies including products to conserve and improve energy. These IXYS technologies are well known in the market place to improve power conversion efficiency, generate clean energy, improve automation, and provide advanced products for the transportation, medical and telecommunication industries.

IXYS is a pioneer in the development of power semiconductors and high voltage integrated circuits that are essential to reducing the world’s dependence on fossil fuels. Diminishing natural resources, demand for cheap energy and environmental directives for energy efficiency represent a significant challenge. IXYS’ power semiconductors and mixed-signal integrated circuits play a vital role in reducing energy costs and consumption by optimizing the energy efficiency of everyday products.

With over 2,000 customers in telecommunications, transportation, industrial, medical and consumer companies, IXYS is a worldwide provider of semiconductors. Additional information may be obtained by visiting IXYS’ website at http://www.ixys.com, or by contacting the company directly.

About Zilog, Inc.

Zilog is a trusted supplier of application-specific, embedded system-on-chip solutions for the industrial and consumer markets. From its roots as an award-winning architect in the microprocessor and microcontroller industry, Zilog has evolved its expertise beyond core silicon to include SoCs, single board computers, application specific software stacks and development tools that allow embedded designers quick time to market in areas such as energy management, monitoring and metering and motion detection. For more information, visit http://www.zilog.com.

Safe Harbor Statement

This press release includes forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, that are subject to risks, uncertainties and other factors, including the risks to both companies that the acquisition of Zilog will not be consummated, as the transaction is subject to certain closing conditions. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including statements regarding the expected timing of the completion of the transaction; the ability to complete the transaction considering the various closing conditions; any projections of earnings, revenues or other financial items; any statements of the plans, strategies and objectives of management for future operations; any statements regarding product development, product extensions, product integration or product marketing; any statements of expectation or belief; and any statements of assumptions underlying any of the foregoing. In addition, if and when the transaction is consummated, there will be risks and uncertainties related to IXYS’ ability to successfully integrate the products and employees of IXYS and Zilog, as well as the ability to ensure continued performance or market growth of Zilog’s products. These risks, uncertainties and other factors, and the general risks associated with the respective businesses of IXYS and Zilog described in the reports and other documents filed by each of them with the Securities and Exchange Commission, could cause actual results to differ materially from those referred to in the forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. All forward-looking statements are based on information currently available to IXYS and Zilog and are qualified in their entirety by this cautionary statement. Neither IXYS nor Zilog assumes any obligation to update any such forward-looking statements or other statements included in this press release.

Additional Information about the Transaction and Where to Find It

In connection with the proposed acquisition, Zilog will file a proxy statement with the SEC. Additionally, IXYS and Zilog will file other relevant materials in connection with the proposed acquisition of Zilog by IXYS pursuant to the terms of an Agreement and Plan of Merger by and among IXYS, Zanzibar Acquisition, Inc., a wholly-owned subsidiary of IXYS, and Zilog. Investors and security holders of Zilog are urged to read the proxy statement and the other relevant materials when they become available before making any voting or investment decision with respect to the proposed acquisition because they will contain important information about the acquisition and the parties to the acquisition.

Investors and security holders may obtain a free copy of these documents (when available) and other documents filed by Zilog at the SEC’s web site at www.sec.gov. The proxy statement and such other documents may also be obtained for free from Zilog by directing such request to Zilog, Inc., Attention: Daniel Francisco, Telephone: (916) 812-8814, E-mail: dan@franciscogrp.com, or Attention: Perry Grace, 6800 Santa Teresa Blvd., San Jose, CA 95119, Telephone: (408) 513-1555, E-mail: pgrace@zilog.com.

IXYS, Zilog and their respective directors, executive officers and other members of management and employees, under SEC rules, may be deemed to be participants in the solicitation of proxies of Zilog stockholders in connection with the proposed acquisition. Investors and security holders may obtain more detailed information regarding the names, affiliations and interests of certain of IXYS’s executive officers and directors in the solicitation by reading the proxy statement and other relevant materials filed with the SEC when they become available. Information concerning the interests of Zilog’s participants in the solicitation, which may, in some cases, be different than those of Zilog’s stockholders generally, is set forth in the materials filed with the SEC on Form 10-K and will be set forth in the proxy statement relating to the acquisition when it becomes available.

AsiaInfo (ASIA) and Linkage to Merge

BEIJING and SANTA CLARA, Calif., Dec. 6 /PRNewswire-FirstCall/ — AsiaInfo Holdings, Inc. (Nasdaq: ASIA) (“AsiaInfo” or “the Company”) and Linkage Technologies International Holdings Limited (“Linkage”), leading providers of software solutions and IT services for the telecommunications industry in China, today jointly announced that they have signed a definitive agreement to merge, forming AsiaInfo-Linkage, Inc. (“AsiaInfo-Linkage”). The transaction will leverage both AsiaInfo’s and Linkage’s leading market positions and complementary customer bases to provide a robust, full-service offering to telecom operators.

Under the terms of the agreement, Linkage shareholders will receive US$60 million in cash and approximately 26.8 million AsiaInfo shares upon closing of the transaction. Based on the closing price of AsiaInfo’s stock on December 4, 2009, the combined company would have a market value of over US$1.8 billion. Post-transaction, Linkage’s legacy shareholders will own approximately 35.8% of AsiaInfo-Linkage with AsiaInfo’s legacy shareholders owning approximately 64.2%. The transaction is expected to be accretive to non-GAAP earnings per share in 2010.

Upon completion of the transaction, AsiaInfo-Linkage will have over 8,000 employees, of which approximately 7,000 are engineers dedicated to project delivery and research and development. The combined company will also have 34 patents and an additional 27 patents pending approval in China and the United States.

“We are creating the pre-eminent software solutions provider in China’s telecommunications industry,” said Mr. Steve Zhang, AsiaInfo’s president and chief executive officer. “The combined company’s expanded service offering, extensive base of highly skilled engineers, world class R&D capabilities and complementary customer bases will enable us to better service and anticipate our customers’ needs. Going forward, we will leverage our products and services which range from system implementation and maintenance services to high-value consulting in order to capitalize on China’s fast-growing telecom software industry. In addition to growing our business domestically, the merged company will explore new revenue drivers by looking abroad.”

“This is a very exciting development and milestone for our company and an important move that will benefit China’s telecom software industry,” commented Mr. Libin Sun, Linkage’s chairman and chief executive officer. “For more than 10 years, AsiaInfo and Linkage have developed innovative products, built strong relationships with all three telecom operators in China and have delivered strong financial results. In fact, from 2006 to 2008, Linkage’s total revenues and net income grew at compounded annual growth rates of approximately 37.4% and 36.5%, respectively. With common business strategies and a plan to fully integrate our management teams and internal systems, I am confident that we will be able to quickly identify business opportunities and realize value for our shareholders.”

Upon closing, Mr. Steve Zhang, AsiaInfo’s president and chief executive officer, will become president and chief executive officer of AsiaInfo-Linkage. AsiaInfo-Linkage’s board of directors will comprise of nine members, consisting of six members from AsiaInfo’s board and three members appointed by Linkage’s board. Mr. Libin Sun, Linkage’s chairman and chief executive officer, will serve as AsiaInfo-Linkage’s executive co-chairman and Mr. James Ding, AsiaInfo’s chairman, will serve as AsiaInfo-Linkage’s co-chairman.

The merger has been approved by both companies’ boards of directors and is subject to customary closing conditions including the receipt of any regulatory approvals and the approval of AsiaInfo’s shareholders. The transaction is expected to close by the end of the first quarter or early in the second quarter of 2010.

BofA Merrill Lynch and The Hina Group acted as financial advisors and DLA Piper and Han Kun Law Office acted as legal advisors to AsiaInfo in connection with the transaction. Barclays Capital served as financial advisor and Latham & Watkins and Global Law Office served as legal advisers to Linkage.

Conference Call Details

AsiaInfo management will hold a conference call at 5:00 a.m. Pacific Time / 8:00 a.m. Eastern Time on December 7, 2009 (9:00 p.m. Beijing/Hong Kong Time on December 7, 2009). Management will discuss the merger in more detail and answer questions from analysts and investors.

The dial-in numbers for the conference call are as follows:

U.S. Toll Free: +1-888-830-9551

China Toll Free Number (China Netcom): 10800-852-1039

China Toll Free Number (China Telecom): 10800-152-1039

Hong Kong and International: +852-3002-1675

The passcode for the conference call is 67339161.

A replay of the call will be available until 8:00 a.m. Eastern Time on December 22, 2009 by dialing one of the following numbers:

U.S. Toll Free: +1-617-213-4164

Hong Kong and International: +852-3011-4542

The passcode for the replay of the conference call is 67339161.

Additionally, a PowerPoint will be posted under the investor relations section of the company’s website which can be downloaded and used to follow along on the call.

About AsiaInfo Holdings, Inc.

AsiaInfo Holdings, Inc. (Nasdaq: ASIA) is a leading provider of high-quality software and customer solutions to many of China’s largest enterprises. In addition to providing software and customer solutions to China’s telecom carriers, the Company also offers a wide range of security products and services to small, medium and large sized Chinese enterprises across multiple vertical industries.

Organized as a Delaware corporation, AsiaInfo began operations in the United States in 1993. The Company moved its major operations to China in 1995 and played a significant role in the construction of the national Internet backbones and provincial access networks for all of China’s major national telecom carriers, including China Telecom, China Mobile and China Unicom. Since 1998, AsiaInfo has continued to diversify its product offerings and is now a major provider of enterprise software solutions in China.

For more information about AsiaInfo, please visit http://www.asiainfo.com.

Linkage Technologies International Holdings Limited

Linkage Technologies International, based in Nanjing, China, was founded in 1997 and is a leading provider of software solutions and IT services for the telecom industry in China. The company develops and implements Business Support Systems (“BSS”), Operation Support Systems (“OSS”) and Business Intelligence Systems (“BI”) for all three operators in China.

For more information about Linkage, please visit http://www.lianchuang.com.

Cautionary Note Regarding Forward-Looking Statements

The information contained in this press release is as of December 6, 2009. We assume no obligation to update any forward-looking statements contained in this press release as a result of new information or future events or developments. This press release contains forward-looking information about future performance, revenue and cost synergies, cross-selling opportunities and other anticipated outcomes of the business combination of AsiaInfo Holdings and Linkage Technologies. Among the factors that could cause actual results to differ materially are the following: the anticipated timing of filings and approvals relating to the proposed business combination; the satisfaction of other closing conditions; the expected timing of the completion of the acquisition; the ability to successfully integrate the products, services and employees of AsiaInfo and Linkage; the ability to successfully develop and market new products and services, and the uncertainty of whether our products and services will achieve market acceptance or result in revenue growth; and the continued performance or market growth of the combined company’s products and services. A further list and description of these risks, uncertainties, and other matters can be found in AsiaInfo’s Annual Report on Form 10-K for the fiscal year ended December 31, 2008, and in our periodic reports on Forms 10-Q and 8-K filed with the United States Securities and Exchange Commission and available at www.sec.gov.

ASIAINFO HOLDINGS INTENDS TO FILE A PROXY STATEMENT WITH THE SECURITIES AND EXCHANGE COMMISSION (THE “SEC”) RELATING TO ASIAINFO’S SOLICITATION OF PROXIES FROM THE SHAREHOLDERS OF ASIAINFO FOR USE AT A SPECIAL MEETING OF SHAREHOLDERS. ALL ASIAINFO SHAREHOLDERS ARE URGED TO READ THE PROXY STATEMENT FILED WITH THE SEC CAREFULLY IN ITS ENTIRETY WHEN IT BECOMES AVAILABLE BECAUSE IT WILL CONTAIN IMPORTANT INFORMATION. SHAREHOLDERS WILL BE ABLE TO OBTAIN FREE COPIES OF THE PROXY STATEMENT FILED WITH THE SEC BY ASIAINFO AT WWW.ASIAINFO.COM, AND THROUGH THE WEB SITE MAINTAINED BY THE SEC AT WWW.SEC.GOV.

XATA Corp. (XATA) Raises $30M in Financing, Acquires Turnpike Global

MINNEAPOLIS, Dec. 4 /PRNewswire-FirstCall/ — XATA Corporation (Nasdaq: XATA), today announced it has received $30 million in funding from Technology Crossover Ventures (TCV) and Trident Capital, and that it has purchased Ontario Canada-based Turnpike Global Technologies (Turnpike) for $20 million in cash and stock.

TCV is one of the largest venture capital firms focused solely on information technology, with more than $7.7 billion under management. Its investment in XATA will facilitate the acquisition of Turnpike and provide added capital to accelerate XATA’s growth, eliminate debt and strengthen its balance sheet. Trident Capital–a longtime XATA investor–is also participating in the new investment.

“XATA Corporation is a strategic portfolio company that brings strong technology and management leadership and exemplifies the tremendous growth potential in the transportation management market,” said Woody Marshall, TCV general partner. “We are pleased to invest in the company and we look forward to working with the XATA team to further accelerate its expansion.”

Purchasing Turnpike, a PDA-based fleet operations solutions provider, will allow XATA to continue its growth strategy by expanding XATA’s addressable market to include small and medium-size fleets in North America and key vertical markets, such as Less Than Truckload (LTL) and beverage, where Turnpike’s product functionality meets specific customer needs. With the acquisition, XATA has more than 100,000 systems deployed with over 1,400 customers across North America. The acquisition will also expand XATA’s product portfolio and expertise in the PDA market and distribution through channel partners, such as Sprint and AT&T.

“TCV has a strong reputation and history of success,” said Jay Coughlan, president and CEO of XATA. “Our alignment with TCV and the acquisition of Turnpike are clear indicators of our intention to aggressively move forward as a leading provider of Fleet Performance Management solutions. This alignment also reinforces our strategy of continuing to consolidate the market through strategic acquisitions. With the Turnpike acquisition, we significantly expand the markets we service, more easily expand our hardware flexibility to PDAs and better fulfill our mission of serving the market overall.”

“This is an exciting milestone for our company. XATA is a recognized leader of fleet optimization solutions and the perfect company for us to scale our growth,” said Brendan Staub, president and chief executive officer of Turnpike. “Jointly, we can go to market with solutions ranging from self-explanatory products to totally integrated systems that will create exciting growth opportunities for our customers and our employees.”

Under the acquisition, Turnpike will operate as a division of XATA, with Turnpike’s divisional management reporting to the XATA executive team. Turnpike’s fleet operation applications, such as its end-to-end fuel tax process, are a perfect complement to XATA’s XATANET Fleet Performance Management solution.

About TCV

Technology Crossover Ventures (TCV), founded in 1995, is a leading provider of growth capital to technology companies, providing funds to later-stage private and public companies. With $7.7 billion in capital under management, TCV has made growth equity and recapitalization investments in over 170 companies leading to 45 initial public offerings and more than 30 strategic sales or mergers. Representative investments include Altiris, eHarmony, Expedia, Fandango, Liquidnet, Netflix, RealNetworks, Redback Networks, Solect Technology, TechTarget, Travelport, Webroot, and Zillow. TCV has 11 partners and is headquartered in Palo Alto, California. For more information about TCV, visit www.tcv.com.

About Trident Capital

Trident Capital is a venture capital and private equity firm founded in 1993 by industry veterans. Since then, the firm has grown to more than 20 investment professionals with $1.5 billion under management invested in more than 150 companies. The firm’s active investment approach has helped dozens of companies, such as MapQuest and iRobot, to realize successful exits. Trident specializes in business services, information services and software, including technology-leveraged outsourcing and processing for healthcare and insurance, marketing and sales, and enterprise software for security, communications and mobility.

Trident’s partners have over 100 years of collective operating experience, and bring extensive industry knowledge and contacts to entrepreneurs and their teams to help them achieve the level of success they deserve. Dedicated to building businesses with strong infrastructures and putting them on the path to profitability, Trident works with innovative businesses to help them maximize their growth potential.

About Turnpike Global Technologies

Based in Toronto, ON, Turnpike Global Technologies provides simple solutions to the transportation industry that result in immediate cost savings. Turnpike has been recognized as the first company in North America to fully automate, from end-to-end, the fuel and mileage tax process required by the International Fuel Tax Agreement (IFTA). It’s RouteTracker, a fleet management device, connects directly to the engine diagnostic port of medium and heavy duty trucks to collect and report on operational statistics, GPS position and automate compliance information. RouteTracker interacts with various handheld devices using Bluetooth as a wireless in-cab communication medium. The information collected by RouteTracker is made available to the end-user via web-based reporting. RouteTracker installation takes an average of only 10 minutes per truck.

About XATA

XATA (NASDAQ:XATA) is the expert in optimizing fleet operations by reducing costs and ensuring regulatory compliance for the trucking industry. Our on-demand software and services help companies manage fleet operations, enhance driver safety and deliver a higher level of customer satisfaction. Offered through a fee-based subscription service, XATA affordably oversees every truck in an organization’s fleet. XATA provides expert services to develop the business processes required to deliver the profitability, safety and service levels demanded by today’s competitive transportation environments.

Based in Minneapolis, Minnesota, XATA revolutionized the trucking industry by being the first to introduce electronic driver logs and exception-based management reporting with automatic fleet information updates, giving our customers access to vehicle data, anywhere, anytime.

Cautionary note regarding forward-looking statements.

This announcement includes forward-looking statements. Statements that are not historical or current facts, including statements about beliefs and expectations, are forward-looking statements. Such statements are based on current expectations, and actual results may differ materially. The forward-looking statements in this announcement are subject to a number of risks and uncertainties including, but not limited to, the possibility of continuing operating losses, the ability to adapt to rapid technological change, cost and difficulties we may face in integrating the businesses of XATA and GeoLogic Solutions, dependence on positioning systems and communication networks owned and controlled by others, the receipt and fulfillment of new orders for current products, the timely introduction and market acceptance of new products, the ability to fund future research and development activities, the ability to establish and maintain strategic partner relationships, and the other factors discussed under “Risk Factors” in Part IA, Item 1 of our Annual Report on Form 10-K for the fiscal year ended September 30, 2008 (as updated in our subsequent reports filed with the SEC). These reports are available under the “Investors” section of our Web site at www.xata.com and through the SEC Web site at www.sec.gov. Forward-looking statements speak only as of the date they are made, and we undertake no obligation to update them in light of new information or future events.

Tianyin Pharmaceutical Co., Inc. (TPI) Provides Fiscal 2011 Guidance

CHENGDU, China, Dec. 3, 2009 (PRNewswire-Asia-FirstCall) —

— Management expects to report revenues of approximately $113.3 million and net income of approximately $19.6 million for the Fiscal Year which ends June 30, 2011, representing approximately 78.1% and 73.5% growth over fiscal 2010 guidance

Tianyin Pharmaceutical, Co., Inc., (NYSE Alternext: TPI), a manufacturer and supplier of modernized traditional Chinese medicine (“TCM”) based in Chengdu, China, today announced financial guidance for fiscal year 2011. The forecasted revenue of $113.3 million for fiscal 2011 will represent a 78.1% increase over the projected fiscal year 2010 revenues of $63.6 million, while the forecasted net income of $19.6 million will represent a 73.5% increase over the projected net income of $11.3 million for fiscal 2010.

Growth will be driven by increased revenues from the Company’s existing product portfolio and new products commercialized from its pipeline, in addition to the wholesale initiative for branded specialty products, which are collectively expected to contribute approximately $90.8 in revenues and $18.2 in net income. The recently announced Sichuan Jiangchuan Pharmaceutical Co. Ltd. joint venture for macrolide antibiotic API production is expected to contribute approximately $22.5 million in revenues and $1.4 million in net income.

These forecasts do not include any potential future acquisitions or joint venture agreements. The company is currently evaluating several acquisition opportunities, including companies with complementary product portfolios, and those which would accelerate the macrolide antibiotic business growth strategy.

“It’s important for our shareholders to understand the management’s vision for building a successful pharmaceutical company through both organic growth and accretive acquisitions. My previous CEO experience building Kehlun Pharmaceuticals into a $1 Billion IV solution product company in China has helped me gain the necessary management skill sets and business network to accomplish these goals. The current favorable growth dynamics in the pharmaceutical industry and the rapid surge in China’s domestic consumption give us confidence that our timing for accelerating Tianyin’s expansion is just right and we are very optimistic about our Company’s future,” commented Dr. Guoqing Jiang, Chairman and CEO of Tianyin Pharmaceutical, Inc.

“We are very pleased to report that growth in our core business is accelerating as demand for key products, including Ginko Mihuan, underscores the importance of having a portfolio of branded pharmaceuticals which address large market opportunities. The recent SFDA approval for these 2 new products are expected to be meaningful contributors and complement the 10 products we launched in the past year to further diversify our product base. Enhanced capacity, supported by our new production facility, and broader distribution channels provide the foundation for significant long term revenue growth,” Dr. Jiang concluded.

About Tianyin Pharmaceuticals

Tianyin is a manufacturer and supplier of modernized Traditional Chinese Medicine (“TCM”) in China. It was established in 1994 and acquired by the current management team in August 2003. It has a comprehensive product portfolio of 39 products, 22 of which are listed in the highly selective National Medicine Catalog of the National Medical Insurance program. Tianyin owns and operates two GMP manufacturing facilities and an R&D platform supported by leading Chinese academic institutions. The Company has a pipeline of 17 pharmaceutical products pending approval. Tianyin has an extensive nationwide distribution network throughout China with a sales force of 720 salespeople. Tianyin is headquartered in Chengdu, Sichuan Province with two manufacturing facilities and a total of 1,365 employees. For more information about Tianyin, please visit http://www.tianyinpharma.com .

Safe Harbor Statement

The Statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company’s filings with the Securities and Exchange Commission.

Energy Recovery (ERII) PX Devices Implemented in World’s First Osmotic Power Plant

Dec. 3, 2009 (Business Wire) — Energy Recovery, Inc. (NASDAQ:ERII), a leader in the design and development of energy recovery devices for desalination, today announced that its industry-leading PX Pressure Exchanger® energy recovery devices are implemented at the world’s first osmotic power plant. Built in Tofte, Norway, by leading Norwegian energy company Statkraft, the pilot plant showcases how the energy created through osmosis can be harnessed to generate a continuous source of renewable electricity. The high efficiency of Energy Recovery’s PX devices increase the energy output and reduce the energy consumed during the osmotic power generation process to ensure the net-positive production of electricity.

“The commissioning of our pilot facility is a significant step toward the commercialization of this game-changing renewable energy source. According to our calculations, the global production potential of osmotic power could exceed 1,600 terawatt hours, or the equivalent of half of Europe’s entire energy demand,” said Stein Erik Skilhagan, vice president of osmotic power at Statkraft. “Although osmotic power has enormous potential, it is only economically feasible if you reduce the cost of creating it. Energy Recovery’s PX devices address this issue by considerably reducing energy use, allowing us to produce renewable electricity. We anticipate that the pilot plant will be quite successful and plan to implement the PX technology as we scale up to a commercial facility.”

Energy Recovery’s PX devices are currently deployed at large seawater reverse osmosis (SWRO) desalination plants all over the world. By recycling the energy typically wasted as part of the reject stream, the PX devices—which operate at 98 percent efficiency—reduce energy use by up to 60 percent, helping to make desalination an affordable solution to global water scarcity. Energy Recovery’s devices function on a similar principle in osmotic power processes.

The osmotic power process harnesses the osmotic potential difference between saltwater (such as seawater) and freshwater to produce a pressurized stream of membrane permeate. Diluted saltwater is released through a turbine that turns a generator to produce electricity. The PX devices work in unison with next-generation forward osmosis membranes to cost-effectively enable stable, reliable, environmentally friendly energy production anywhere that both freshwater and saltwater are available. The pilot plant in Tofte, Norway is designed to produce 10 kW of renewable energy, and by 2015, Statkraft plans to build a full-scale osmotic power plant capable of producing 25 MW of electricity.

“The ability to harness osmosis and turn it into a continuous supply of clean, renewable energy is an extremely important accomplishment for humanity and the environment. We applaud Statkraft on opening the pilot facility as a major milestone for osmotic power,” said Rick Stover, CTO of Energy Recovery, Inc. “We look forward to further developments in osmotic power technology, which could potentially use any saltwater or solution with a high osmotic potential to generate electricity. In every case, PX energy recovery devices will be an essential component, maintaining high osmotic pressure and maximizing net power output through high-efficiency performance. We look forward to playing an important role as osmotic power evolves as a significant source of global energy.”

About ERI

Energy Recovery, Inc. (NASDAQ:ERII) designs and develops energy recovery devices that help make desalination affordable by significantly reducing energy consumption. ERI’s PX Pressure Exchanger™ (PX™) device is a rotary positive displacement pump that recovers energy from the high pressure reject stream of seawater reverse osmosis systems at up to 98% efficiency. With more than 7,000 PX devices deployed or under contract to be installed in desalination plants across the globe, ERI’s technology has set the industry standard for energy recovery devices for desalination. The company is headquartered in the San Francisco Bay Area with offices in key desalination centers worldwide, including Madrid, Shanghai, Florida and the United Arab Emirates. For more information on ERI and PX technology, please visit www.energyrecovery.com.

Forward Looking Statements

This press release includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements include statements about the market potential for ERI’s products in emerging osmotic power applications. Because such forward-looking statements involve risks and uncertainties, including the risk that the potential for osmotic power generation and the resulting increase in demand for ERI’s products may not be realized, the Company’s actual results may differ materially from those suggested by the forward-looking statements. All forward-looking statements are made as of today, and the Company assumes no obligation to update such statements. For more details relating to the risks and uncertainties that could cause actual results to differ materially from those anticipated in our forward-looking statements, please refer to the Company’s SEC filings.

UTi Worldwide (UTIW) Reports Fiscal 2010 Third Quarter Results

LONG BEACH, Calif., Dec. 3, 2009 (GLOBE NEWSWIRE) — UTi Worldwide Inc. (Nasdaq:UTIW) today reported financial results for its fiscal 2010 third quarter ended October 31, 2009.

 Fiscal Third Quarter 2010 vs. 2009 Results:

 * Revenues were $967.2 million, a decrease of 20 percent from
   $1,210.1 million.
 * Net revenues (revenues minus purchased transportation costs)
   were $361.5 million, a decrease of 11 percent from $408.2
   million.
 * Volumes improved sequentially with airfreight and ocean freight
   outpacing the market.
 * Operating income was $31.4 million, a decrease of 42 percent
   from $53.8 million.
 * Income from continuing operations attributable to UTi Worldwide
   Inc. was $18.0 million, or $0.18 per diluted share, compared to
   $35.8 million, or $0.36 per diluted share.

Eric W. Kirchner, chief executive officer, said, “Declines in revenue moderated considerably on a year-over-year basis in the third quarter. Volumes improved throughout the third quarter, particularly in airfreight which experienced an increase in the month of October, the first increase since early 2008. Our sales focus has helped us outpace the market, which we have not accomplished in more than a year. But this improvement was largely offset by industry-wide yield pressure as carriers raised rates substantially, particularly out of Asia. These higher rates could not always be recovered in the near term. While yield contraction was widely expected in the second half of the year, the squeeze was greater than anticipated in the third quarter because of aggressive carrier actions. We are planning for yields to trend towards historic levels as carrier rates adjust to better reflect supply and demand.

“Our overall operating margin continued to show improvement on a sequential basis. Our contract logistics business performed quite well with margins in this segment continuing to move higher in the quarter. And our year-to-date free cash flow continues to approximate net income.”

The decrease in revenues in the 2010 fiscal third quarter compared to the prior-year third quarter of 20 percent was primarily due to substantially reduced fuel surcharges, and to a lesser extent, pricing declines and lower ocean freight and distribution volumes. Net revenue decreased 11 percent principally due to yield pressure in the quarter. On an organic, constant currency basis, adjusted net revenue declined 13 percent compared to the third quarter a year ago.

Operating expenses in the third quarter of fiscal 2010, excluding purchased transportation costs, were $330.1 million, representing a decrease of seven percent compared to the same period last year. The decrease reflects the downsizing of the business and the ongoing discipline to maintain the benefits achieved through our earlier cost reduction efforts. These savings have been somewhat offset by additional operating costs associated with new business successes in both freight forwarding and contract logistics. Operating expenses in the fiscal 2010 third quarter also included severance charges of $2.5 million.

At the beginning of fiscal 2010, the company announced a targeted annual cost savings plan of $50 million against its fiscal 2009 fourth quarter run-rate. Year-to-date the company remains on track to achieve this target though savings realized through the plan have been obscured by the weakening U.S. dollar and partially offset by operating costs associated with new business. On a comparative, constant currency basis consistent with the fourth quarter run-rate, operating expenses were $10.4 million lower in the fiscal 2010 third quarter and $38.9 million lower year-to-date, on track with the $50 million target. A reconciliation of fiscal 2010 operating expenses to the fourth quarter run-rate is provided in the tables attached to this press release.

The company reported operating income in the fiscal 2010 third quarter of $31.4 million, which represented 8.7 percent of net revenues. This compares to operating income in the year-ago third quarter of $53.8 million, or 13.2 percent of net revenues.

Investor Conference Call:

UTi management will host an investor conference call today, December 3, 2009, at 8:00 a.m. PST (11:00 a.m. EST) to review the company’s financials and operations for the fiscal 2010 third quarter. Investment professionals are invited to participate in the live call by dialing 877-570-6091 (domestic) or 702-696-4824 (international) using conference ID 42511216. The call will be open to all interested investors through a live, listen-only audio Internet broadcast at www.go2uti.com and www.earnings.com. For those who are not available to listen to the live broadcast, the call will be archived for one year at both Web sites. A telephonic playback of the conference call also will be available from approximately 11:00 a.m. PST, today, through December 11, 2009, by calling 800-642-1687 (domestic) or 706-645-9291 (international) and using replay passcode 42511216.

About UTi Worldwide:

UTi Worldwide Inc. is an international, non-asset-based supply chain services and solutions company providing air and ocean freight forwarding, contract logistics, customs brokerage, distribution, inbound logistics, truckload brokerage and other supply chain management services. The company serves a large and diverse base of global and local companies, including clients operating in industries with unique supply chain requirements such as the pharmaceutical, retail, apparel, chemical, automotive and technology industries. The company seeks to use its global network, proprietary information technology systems, relationships with transportation providers, and expertise in outsourced logistics services to deliver competitive advantage to each of its clients’ supply chains.

Use of Non-GAAP Financial Information

This press release includes “non-GAAP financial measures” within the meaning of the Securities and Exchange Commission rules. UTi believes that meaningful analysis of its financial performance requires an understanding of the factors underlying that performance and the company’s judgments about the likelihood that particular factors will repeat. Short-term patterns and long-term trends may be obscured by the impact of certain items. For this reason, the company has referred to revenue and net revenue growth adjusted to exclude the impact of dispositions and acquisitions made since the beginning of the comparative period and the impact of currency fluctuations between comparable periods, and to operating expenses adjusted to exclude purchased transportation costs, certain severance and related charges and the impact of acquisitions made since the beginning of the comparative period and the impact of currency fluctuations between comparable periods. This information is among the information the company uses as a basis for evaluating company performance on a comparable basis over time, allocating resources and planning and forecasting of future periods. The company has also provided this information because such adjustments make performance information more comparable to prior disclosures for investors, and may enhance the ability of investors to analyze the company’s performance. This information is not intended to be considered in isolation or as a substitute for the relevant measures calculated in accordance with U.S. GAAP.

Safe Harbor Statement:

Certain statements in this news release may be deemed to be forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. The company intends that all such statements be subject to the “safe-harbor” provisions contained in those sections. Such statements may include, but are not limited to, the company’s discussion of the macroeconomic environment, its sales efforts and the anticipated impact thereof, yield expectations and the outlook for the future. Many important factors may cause the company’s actual results to differ materially from those discussed in any such forward-looking statements, including but not limited to the global economic slowdown that is adversely affecting trade volumes and the financial condition of many of the company’s customers; planned or unplanned consequences of the company’s sales initiatives, procurement initiatives and business transformation efforts; the demand for the company’s services; the impact of cost reduction measures recently undertaken by the company; the costs and impact of the company’s information technology restructuring plan; integration risks associated with acquisitions; increased competition; the impact of volatile fuel costs; the effects of changes in foreign exchange rates; changes in the company’s effective tax rates; industry consolidation making it more difficult to compete against larger companies; general economic, political and market conditions, including those in Africa, Asia and EMENA; work stoppages or slowdowns or other material interruptions in transportation services; risks of international operations; risks associated with, and costs and expenses the company will incur as a result of, the ongoing publicly announced U.S. Department of Justice and other governmental investigations into the pricing practices of the air cargo transportation industry and other similar or related investigations and lawsuits; the success and effects of new strategies and of the realignment of the company’s executive management structure; disruptions caused by epidemics, conflicts, wars and terrorism; and the other risks and uncertainties described in the company’s filings with the Securities and Exchange Commission. Although UTi believes that the assumptions underlying the forward-looking statements are reasonable, any of the assumptions could prove inaccurate and, therefore, the company cannot assure the reader that the results contemplated in forward-looking statements will be realized in the timeframe anticipated or at all. In light of the significant uncertainties inherent in the forward-looking information included herein, the inclusion of such information should not be regarded as a representation by UTi or any other person that UTi’s objectives or plans will be achieved. Accordingly, investors are cautioned not to place undue reliance on the company’s forward-looking statements. UTi undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

 UTi Worldwide Inc.
 Condensed Consolidated Statements of Income
 (in thousands, except share and per share amounts)

                    Three months ended           Nine months ended
                        October 31,                 October 31,
                --------------------------  --------------------------
                    2009          2008          2009          2008
                ------------  ------------  ------------  ------------
 Revenues:       (Unaudited)   (Unaudited)   (Unaudited)   (Unaudited)
  Airfreight
   forwarding   $    328,746  $    428,521  $    838,044  $  1,334,035
  Ocean freight
   forwarding        238,333       326,994       635,947       954,453
  Customs
   brokerage          25,231        28,275        68,543        86,932
  Contract
   logistics         175,157       172,913       475,819       515,126
  Distribution       109,549       151,418       312,563       457,124
  Other               90,182       101,986       245,140       301,974
                ------------  ------------  ------------  ------------
    Total
     revenues        967,198     1,210,107     2,576,056     3,649,644
                ------------  ------------  ------------  ------------
 Operating
  expenses:
  Purchased
   transport-
   ation costs:
    Airfreight
     forwarding      254,576       342,076       627,838     1,061,563
    Ocean
     freight
     forwarding      191,431       270,989       506,706       799,433
    Customs
     brokerage         2,283         1,302         4,965         4,857
    Contract
     logistics        31,971        24,309        84,149        70,144
    Distribution      75,094       107,688       210,992       327,761
    Other             50,308        55,581       130,998       172,240

  Staff costs        196,675       211,881       559,141       651,304
  Depreciation
   and
   amortization       11,393        10,727        31,738        31,932
  Amortization
   of intangible
   assets              2,696         3,458         8,145         9,639
  Restructuring
   charges                --            --         1,231         6,036
  Other
   operating
   expenses          119,355       128,252       338,477       393,610
                ------------  ------------  ------------  ------------
    Total
     operating
     expenses        935,782     1,156,263     2,504,380     3,528,519
                ------------  ------------  ------------  ------------
 Operating
  income              31,416        53,844        71,676       121,125
 Interest
  expense, net        (4,154)       (4,091)       (9,905)      (12,689)
 Other income/
  (expense), net         742         1,047          (256)        1,680
                ------------  ------------  ------------  ------------
   Pretax income      28,004        50,800        61,515       110,116
 Provision for
  income taxes         7,537        14,237        17,761        29,692
                ------------  ------------  ------------  ------------
   Income from
    continuing
    operations,
    net of tax        20,467        36,563        43,754        80,424

 Discontinued
  operations:
   Operating
    income, net
    of tax                --            --            --           100
   Gain on sale,
    net of tax            --         2,088            --         7,404
                ------------  ------------  ------------  ------------
    Net income        20,467        38,651        43,754        87,928
 Net income
  attributable
  to non-
  controlling
  interests            2,500           770         4,187         2,759
                ------------  ------------  ------------  ------------
   Net income
    attributable
    to UTi
    Worldwide
    Inc.        $     17,967  $     37,881  $     39,567  $     85,169
                ============  ============  ============  ============

 Basic earnings
  per common
  share
  attributable
  to UTi
  Worldwide Inc.
  common
  shareholders:
   Continuing
    operations  $       0.18  $       0.36  $       0.40  $       0.78
   Discontinued
    operations            --          0.02            --          0.08
                ------------  ------------  ------------  ------------
                $       0.18  $       0.38  $       0.40  $       0.86
                ============  ============  ============  ============
 Diluted
  earnings per
  common share
  attributable
  to UTi
  Worldwide Inc.
  common
  shareholders:
   Continuing
    operations  $       0.18  $       0.36  $       0.39  $       0.77
   Discontinued
    operations            --          0.02            --          0.07
                ------------  ------------  ------------  ------------
                $       0.18  $       0.38  $       0.39  $       0.84
                ============  ============  ============  ============
 Number of
  weighted-
  average common
  shares
  outstanding
  used for per
  share
  calculations:
   Basic
    shares       100,066,261    99,511,519    99,888,487    99,342,654
   Diluted
    shares       101,282,940   100,892,907   101,205,008   100,935,780
 Amounts
  attributable
  to UTi
  Worldwide Inc.
  common
  shareholders:
   Income from
    continuing
    operations,
    net of tax  $     17,967  $     35,793  $     39,567  $     77,665
   Discontinued
    operations:
     Operating
      income,
      net of tax          --            --            --           100
     Gain on
      sale, net
      of tax              --         2,088            --         7,404
                ------------  ------------  ------------  ------------
      Net
       income   $     17,967  $     37,881  $     39,567  $     85,169
                ============  ============  ============  ============

 UTi Worldwide Inc.
 Condensed Consolidated Balance Sheets
 (in thousands)

                                             October 31,   January 31,
                                                2009          2009
                                            ------------  ------------
                                             (Unaudited)

 ASSETS

 Cash and cash equivalents                  $    307,554  $    256,869
 Trade receivables, net                          732,599       645,275
 Deferred income taxes                            23,117        19,192
 Other current assets                            112,919        79,869
                                            ------------  ------------
  Total current assets                         1,176,189     1,001,205

 Property, plant and equipment, net              180,183       163,441
 Goodwill and other intangible assets, net       485,448       442,691
 Investments                                       2,348         2,940
 Deferred income taxes                            20,765        23,831
 Other non-current assets                         20,607        14,578
                                            ------------  ------------
  Total assets                              $  1,885,540  $  1,648,686
                                            ============  ============

 LIABILITIES & EQUITY

 Bank lines of credit                       $     73,548  $     69,978
 Short-term borrowings                             9,682         6,899
 Current portion of long-term borrowings          69,904        66,666
 Current portion of capital lease
  obligations                                     15,936        15,878
 Trade payables and other accrued
  liabilities                                    676,639       593,271
 Income taxes payable                             11,893        10,425
 Deferred income taxes                             1,500         2,493
                                            ------------  ------------
  Total current liabilities                      859,102       765,610

 Long-term borrowings, excluding current
  portion                                        132,688       115,747
 Capital lease obligations, excluding
  current portion                                 22,602        20,754
 Deferred income taxes                            27,377        27,542
 Retirement fund obligations                       8,266         6,947
 Other non-current liabilities                    18,847        19,116

 Commitments and contingencies

 UTi Worldwide Inc. shareholders' equity:
  Common stock                                   458,684       450,553
  Retained earnings                              372,001       338,461
  Accumulated other comprehensive loss           (37,479)     (112,268)
                                            ------------  ------------
   Total UTi Worldwide Inc. shareholders'
    equity                                       793,206       676,746
  Noncontrolling interests                        23,452        16,224
                                            ------------  ------------
   Total equity                                  816,658       692,970
                                            ------------  ------------

   Total liabilities and equity             $  1,885,540  $  1,648,686
                                            ============  ============

 UTi Worldwide Inc.
 Condensed Consolidated Statements of Cash Flows
 (in thousands)

                                                Nine months ended
                                                    October 31,
                                                -----------------
                                                2009          2008
                                            ------------  ------------
                                             (Unaudited)   (Unaudited)

 OPERATING ACTIVITIES:
 Net income                                 $     43,754  $     87,928
 Adjustments to reconcile net income to
  net cash provided by operating
  activities:
   Share-based compensation costs, net             6,354         8,107
   Depreciation and amortization                  31,738        32,157
   Amortization of intangible assets               8,145         9,639
   Deferred income taxes                            (744)           96
   Uncertain tax positions                           256        (1,918)
   Gain on sale of subsidiaries                       --        (7,404)
   Tax benefit relating to share-based
    compensation                                   1,212           868
   Excess tax benefit from share-based
    compensation                                    (130)         (464)
   Gain on disposal of property, plant and
    equipment                                     (6,195)       (1,050)
   Other                                            (171)          801
   Net changes in operating assets and
    liabilities                                  (32,576)      (55,952)
                                            ------------  ------------
     Net cash provided by operating
      activities                                  51,643        72,808

 INVESTING ACTIVITIES:
 Purchases of property, plant and equipment      (21,062)      (39,365)
 Proceeds from disposal of property, plant
  and equipment                                   11,877         2,453
 Proceeds from sale of subsidiary                     --        11,995
 (Increase)/decrease in other non-current
  assets                                            (448)        4,721
 Acquisitions and contingent earn-out
  payments                                        (3,133)      (30,736)
 Other                                               387        (3,735)
                                            ------------  ------------
   Net cash used in investing activities         (12,379)      (54,667)

 FINANCING ACTIVITIES:
 (Decrease)/increase in bank lines of
  credit                                         (20,030)        5,378
 Increase in short-term borrowings                   907           198
 Proceeds from issuance of long-term
  borrowings                                      56,498            --
 Repayment of long-term borrowings               (36,938)         (307)
 Debt issuance costs                              (4,576)           --
 Repayment of capital lease obligations          (17,615)      (18,953)
 Dividends paid to noncontrolling interests         (998)         (567)
 Net proceeds from issuance of ordinary
  shares                                           1,647         4,422
 Excess tax benefit from share-based
  compensation                                       130           464
 Dividends paid                                   (6,027)       (6,141)
                                            ------------  ------------
   Net cash used in financing activities         (27,002)      (15,506)

 Effect of foreign exchange rate changes
  on cash and cash equivalents                    38,423       (44,170)
                                            ------------  ------------
 Net increase/(decrease) in cash and cash
  equivalents                                     50,685       (41,535)
 Cash and cash equivalents at beginning
  of period                                      256,869       289,141
                                            ------------  ------------

 Cash and cash equivalents at end of period $    307,554  $    247,606
                                            ============  ============

 UTi Worldwide Inc.
 Segment Reporting
 (in thousands)
 (Unaudited)

                              Three months ended October 31, 2009
                        ----------------------------------------------

                                     Contract
                                    Logistics
                         Freight       and
                        Forwarding Distribution  Corporate     Total
                        ----------  ----------   ---------     -----

 Revenues               $  642,384  $  324,814  $       --  $  967,198
                        ----------  ----------  ----------  ----------

 Purchased
  transportation
  costs                    485,683     119,980          --     605,663
 Staff costs                89,016     104,114       3,545     196,675
 Depreciation and
  amortization               3,819       7,353         221      11,393
 Amortization of
  intangible assets            963       1,733          --       2,696
 Other operating
  expenses                  41,352      71,100       6,903     119,355
                        ----------  ----------  ----------  ----------
  Total operating
   expenses                620,833     304,280      10,669     935,782
                        ----------  ----------  ----------  ----------

 Operating income/
  (loss)                $   21,551  $   20,534  $  (10,669)     31,416
                        ==========  ==========  ==========
 Interest expense, net                                          (4,154)
 Other income, net                                                 742
                                                            ----------
   Pretax income                                                28,004
 Provision for income
  taxes                                                          7,537
                                                            ----------
   Net income                                                   20,467
 Net income
  attributable to
  noncontrolling
  interests                                                      2,500
                                                            ----------
   Net income
    attributable to
    UTi Worldwide Inc.                                      $   17,967
                                                            ==========

 UTi Worldwide Inc.
 Segment Reporting
 (in thousands)
 (Unaudited)

                              Three months ended October 31, 2008
                        ----------------------------------------------
                                     Contract
                                    Logistics
                         Freight       and
                        Forwarding Distribution  Corporate     Total
                        ----------  ----------   ---------     -----

 Revenues               $  844,813  $  365,294  $       --  $1,210,107
                        ----------  ----------  ----------  ----------

 Purchased
  transportation costs     653,918     148,027          --     801,945
 Staff costs                99,101     110,149       2,631     211,881
 Depreciation and
  amortization               4,213       6,470          44      10,727
 Amortization of
  intangible assets          1,316       2,142          --       3,458
 Other operating
  expenses                  42,424      82,235       3,593     128,252
                        ----------  ----------  ----------  ----------
   Total operating
    expenses               800,972     349,023       6,268   1,156,263
                        ----------  ----------  ----------  ----------

   Operating income/
   (loss)               $   43,841  $   16,271  $   (6,268)     53,844
                        ==========  ==========  ==========
 Interest expense, net                                          (4,091)
 Other income, net                                               1,047
                                                            ----------
   Pretax income                                                50,800
 Provision for income
  taxes                                                         14,237
                                                            ----------
   Income from
    continuing
    operations,
    net of tax                                                  36,563
 Gain on sale of
  discontinued
  operations,
  net of tax                                                     2,088
                                                            ----------
   Net income                                                   38,651
 Net income
  attributable to
  noncontrolling
  interests                                                        770
                                                            ----------
   Net income
    attributable to
    UTi Worldwide Inc.                                      $   37,881
                                                            ==========

 UTi Worldwide Inc.
 Segment Reporting
 (in thousands)
 (Unaudited)

                             Nine months ended October 31, 2009
                        ----------------------------------------------
                                     Contract
                                    Logistics
                         Freight       and
                        Forwarding Distribution  Corporate     Total
                        ----------  ----------   ---------     -----

 Revenues               $1,675,338  $  900,718  $       --  $2,576,056
                        ----------  ----------  ----------  ----------

 Purchased
  transportation costs   1,235,306     330,342          --   1,565,648
 Staff costs               255,318     293,129      10,694     559,141
 Depreciation and
  amortization              11,168      20,145         425      31,738
 Amortization of
  intangible assets          2,776       5,369          --       8,145
 Restructuring charges          --          --       1,231       1,231
 Other operating
  expenses                 117,530     207,994      12,953     338,477
                        ----------  ----------  ----------  ----------
   Total operating
    expenses             1,622,098     856,979      25,303   2,504,380
                        ----------  ----------  ----------  ----------

 Operating income/
  (loss)                $   53,240  $   43,739  $  (25,303)     71,676
                        ==========  ==========  ==========
 Interest expense, net                                          (9,905)
 Other expense, net                                               (256)
                                                            ----------
   Pretax income                                                61,515
 Provision for income
  taxes                                                         17,761
                                                            ----------
   Net income                                                   43,754
 Net income
  attributable to
  noncontrolling
  interests                                                      4,187
                                                            ----------
   Net income
    attributable to
    UTi Worldwide Inc.                                      $   39,567
                                                            ==========

 UTi Worldwide Inc.
 Segment Reporting
 (in thousands)
 (Unaudited)

                              Nine months ended October 31, 2008
                        ----------------------------------------------

                                     Contract
                                    Logistics
                         Freight       and
                        Forwarding Distribution  Corporate     Total
                        ----------  ----------   ---------     -----

 Revenues               $2,547,142  $1,102,502  $       --  $3,649,644
                        ----------  ----------  ----------  ----------

 Purchased
  transportation costs   1,986,297     449,701          --   2,435,998
 Staff costs               301,161     342,822       7,321     651,304
 Depreciation and
  amortization              11,928      19,793         211      31,932
 Amortization of
  intangible assets          3,006       6,633          --       9,639
 Restructuring charges       2,382       3,654          --       6,036
 Other operating
  expenses                 131,704     248,592      13,314     393,610
                        ----------  ----------  ----------  ----------
   Total operating
    expenses             2,436,478   1,071,195      20,846   3,528,519
                        ----------  ----------  ----------  ----------
   Operating income/
    (loss)              $  110,664  $   31,307  $  (20,846)    121,125
                        ==========  ==========  ==========
 Interest expense, net                                         (12,689)
 Other income, net                                               1,680
                                                            ----------
   Pretax income                                               110,116
 Provision for income
  taxes                                                         29,692
                                                            ----------
   Income from
    continuing
    operations,
    net of tax                                                  80,424
 Discontinued
  operations:
   Operating income,
    net of tax                                                     100
   Gain on sale,
    net of tax                                                   7,404
                                                            ----------
    Net income                                                  87,928
 Net income
  attributable to
  noncontrolling
  interests                                                      2,759
                                                            ----------
  Net income
   attributable to
   UTi Worldwide Inc.                                       $   85,169
                                                            ==========

 UTi Worldwide Inc.
 Geographic Reporting
 (in thousands)
 (Unaudited)

                       Three months ended October 31, 2009
                       -----------------------------------

                                                Contract
                         Contract              Logistics
                         Logistics                and
                            and      Freight    Distri-
               Freight    Distri-  Forwarding   bution    Operating
             Forwarding   bution       Net        Net      Income/
               Revenue    Revenue    Revenue    Revenue     (Loss)
              --------   ---------  ---------  ---------  ---------

 EMENA        $215,812   $  64,733  $  59,226  $  41,154  $   1,807
 Americas      129,963     173,378     38,038     97,809     10,838
 Asia Pacific  210,992       9,071     35,851      6,315      9,083
 Africa         85,617      77,632     23,586     59,556     20,357
 Corporate          --          --         --         --    (10,669)
              --------   ---------  ---------  ---------  ---------
  Total       $642,384   $ 324,814  $ 156,701  $ 204,834  $  31,416
              ========   =========  =========  =========  =========

                       Three months ended October 31, 2008
                       -----------------------------------

                                                Contract
                         Contract              Logistics
                         Logistics                and
                            and      Freight    Distri-
               Freight    Distri-  Forwarding   bution    Operating
             Forwarding   bution       Net        Net      Income/
               Revenue    Revenue    Revenue    Revenue     (Loss)
              --------   ---------  ---------  ---------  ---------

  EMENA       $284,813   $  62,985  $  73,542  $  42,080  $  10,646
  Americas     171,385     214,768     44,609    112,639     19,557
  Asia Pacific 289,690       9,723     46,515      6,070     14,882
  Africa        98,925      77,818     26,229     56,478     15,027
  Corporate         --          --         --         --     (6,268)
              --------   ---------  ---------  ---------  ---------
   Total      $844,813   $ 365,294  $ 190,895  $ 217,267  $  53,844
              ========   =========  =========  =========  =========

 UTi Worldwide Inc.
 Geographic Reporting
 (in thousands)
 (Unaudited)

                         Nine months ended October 31, 2009
                      ---------------------------------------

                      Contract            Contract
                      Logistics           Logistics
                         and     Freight     and
             Freight  Distribu-  Forward- Distribu- Operating Restruct-
           Forwarding   tion     ing Net  tion Net   Income/    uring
             Revenue   Revenue   Revenue   Revenue   (Loss)    Charges
           ---------- --------- --------- --------- --------- ---------

 EMENA     $  602,560 $ 178,283 $ 169,152 $ 116,464 $   3,031 $      --
 Americas     349,674   482,762   107,398   270,729    18,396        --
 Asia
  Pacific     517,472    25,859   105,349    18,114    28,203        --
 Africa       205,632   213,814    58,133   165,069    47,349        --
 Corporate         --        --        --        --   (25,303)    1,231
           ---------- --------- --------- --------- --------- ---------
  Total    $1,675,338 $ 900,718 $ 440,032 $ 570,376 $  71,676 $   1,231
           ========== ========= ========= ========= ========= =========

                         Nine months ended October 31, 2008
                      ---------------------------------------

                      Contract            Contract
                      Logistics           Logistics
                         and     Freight     and
             Freight  Distribu-  Forward- Distribu- Operating Restruct-
           Forwarding   tion     ing Net  tion Net   Income/    uring
             Revenue   Revenue   Revenue   Revenue   (Loss)    Charges
           ---------- ---------- -------- --------- --------- ---------

 EMENA     $  878,102 $  201,390 $223,826 $ 127,076 $  30,652 $   1,558
 Americas     502,930    644,148  129,837   342,897    40,286     3,769
 Asia
  Pacific     870,480     26,516  133,798    17,018    38,683       240
 Africa       295,630    230,448   73,384   165,810    32,350       469
 Corporate         --         --       --        --   (20,846)       --
           ---------- ---------- -------- --------- --------- ---------
  Total    $2,547,142 $1,102,502 $560,845 $ 652,801 $ 121,125 $   6,036
           ========== ========= ========= ========= ========= =========

 UTi Worldwide Inc.
 Revenue Growth Reconciliation
 (in thousands)
 (Unaudited)

 Set forth below is a reconciliation of our organic growth in our
 revenues and net revenues over the corresponding prior-year period.

                                REVENUES           NET REVENUES
                              ------------         ------------
 Three months ended
  October 31, 2008            $  1,210,107         $    408,162
 Add: Acquisitions impact (1)        9,909                5,279
 Add: Currency impact (2)            5,528                3,138
 Organic growth                   (258,346) (21)%       (55,044) (13)%
                              ------------  =====  ------------  =====
 Three months ended
  October 31, 2009            $    967,198         $    361,535
                              ============         ============

 (1) Relates to revenues in the current period for businesses acquired
     from August 2008.

 (2) Represents the fluctuations in foreign currency exchange rates
     when balances are translated into U.S. dollars.

 UTi Worldwide Inc.
 Revenue Growth Reconciliation
 (in thousands)
 (Unaudited)

 Set forth below is a reconciliation of our organic growth in our
 revenues and net revenues over the corresponding prior-year period.

                                REVENUES           NET REVENUES
                              ------------         ------------
 Nine months ended
  October 31, 2008            $  3,649,644         $  1,213,646
 Add: Acquisitions impact (1)       26,674               14,448
 Less: Dispositions impact (2)     (22,545)             (22,082)
 Less: Currency impact (3)        (160,299)             (67,156)
 Organic growth                   (917,418) (25)%      (128,448) (11)%
                              ------------  =====  ------------  =====

 Nine months ended
  October 31, 2009            $  2,576,056         $  1,010,408
                              ============         ============

 (1) Relates to revenues in the current period for businesses acquired
     from February 2008.

 (2) Relates to revenues in the corresponding prior period for
     businesses exited through the Company's previously announced
     cost reduction plans.

 (3) Represents the fluctuations in foreign currency exchange rates
     when balances are translated into U.S. dollars.

 UTi Worldwide Inc.
 Operating Expenses Reconciliation
 (in thousands)
 (Unaudited)

 Set forth below is a reconciliation of our fiscal 2010 operating
 expenses in comparison to our adjusted fourth quarter fiscal year 2009
 operating expenses:

                                 Three months ended   Nine months ended
                                  October 31, 2009    October 31, 2009
                                  ----------------    ----------------

 Total operating expenses            $     935,782       $   2,504,380
 Less: Purchased transportation
  costs                                   (605,663)         (1,565,648)
                                  ----------------    ----------------
   Subtotal                                330,119             938,732

 Less: Acquisition impact                   (4,999)            (13,560)
 Less: Severance, restructure
  and other charges                         (2,530)            (11,599)
 Add: Gain on sale of property                  --               6,271
 Less: Currency impact                     (26,987)            (40,739)
                                  ----------------    ----------------
   Adjusted operating expenses       $     295,603        $    879,105
                                  ================    ================

                                 Three months ended
                                  January 31, 2009
                                  ----------------

 Total operating expenses            $     991,904
 Less: Purchased transportation
  costs                                   (561,379)
                                  ----------------
   Subtotal                                430,525

 Less: Severance, restructure
  and other charges                        (14,576)
 Less: Goodwill impairment                (109,941)
                                  ----------------
   Adjusted operating expenses       $     306,008       $     918,024*
                                  ================    ================

 Savings over fourth quarter
  fiscal year 2009 operating
  expenses                           $      10,405       $      38,919
                                  ================    ================

 * This amount represents the adjusted operating expenses for the
   three months ended January 31, 2009 applied over a nine month
   period.

CONTACT:  UTi Worldwide Inc.
          Jeff Misakian, Vice President, Investor Relations
          (562) 552-9417
          jmisakian@go2uti.com

Fuwei Films (FFHL) Announces Receiving RMB 10 Million in Additional Financial Support From Chinese Government

BEIJING — (Marketwire) — 12/03/09 — Fuwei Films (Holdings) Co. Limited (NASDAQ: FFHL) (“Fuwei Films” or the “Company”), a manufacturer and distributor of high-quality BOPET plastic films located in China, today announced that its wholly owned subsidiary — Fuwei Films (Shandong) Co. Ltd. (“Shandong Fuwei”) recently received RMB 10 million financial support in the form of a loan from the local Chinese government.

Since 2008, Chinese companies have been adversely impacted by the global financial crisis. In response to the economic conditions in China, the Chinese government has introduced a series of stimulus packages. In November 2009, the Company received the RMB 10 million financial support after completing the necessary procedures with the local Chinese government. Shandong Fuwei is one of the two companies in the Weifang High-tech Area which has acquired this financial support from the government. Shandong Fuwei is planning to use this project fund in accordance with the needs of the company.

This financial support is an eight-year long-term loan with an interest rate of 5.346% and equal installments of RMB 3.3 million to be paid within 3 years prior to the expiration of the loan.

“We are glad that our subsidiary has been awarded the financial support from the local Chinese government. We believe that this long term loan demonstrates the Chinese government’s endorsement in the long-term outlook of Fuwei Films,” said Mr. Xiaoan He, the chairman and CEO of Fuwei Films. “We will continue to commit ourselves to the operation of the Company and enhance the equity of the shareholders.”

About Fuwei Films

Fuwei Films conducts its business through its wholly owned subsidiary Shandong Fuwei Films Co., Ltd. (“Shandong Fuwei”). Shandong Fuwei develops, manufactures and distributes high-quality plastic films using the biaxial oriented stretch technique, otherwise known as BOPET film (biaxially oriented polyethylene terephthalate). Fuwei’s BOPET film is widely used to package food, medicine, cosmetics, tobacco and alcohol, as well as in the imaging, electronics, and magnetic products industries.

Safe Harbor

This press release contains information that constitutes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and are subject to risks. Risk factors that could contribute to such differences include those matters more fully disclosed in the Company’s reports filed with the U. S. Securities and Exchange Commission some of which are among other things, competition in the BOPET film industry; growth of, and risks inherent in, the BOPET film industry in China; uncertainty as to future profitability and our ability to obtain adequate financing for our planned capital expenditure requirements; uncertainty as to our ability to continuously develop new BOPET film products and keep up with changes in BOPET film technology; risks associated with possible defects and errors in our products; uncertainty as to our ability to protect and enforce our intellectual property rights; uncertainty as to our ability to attract and retain qualified executives and personnel; and uncertainty in acquiring raw materials on time and on acceptable terms, particularly in view of the volatility in the prices of petroleum products in recent years. The forward-looking information provided herein represents the Company’s estimates as of the date of the press release, and subsequent events and developments may cause the Company’s estimates to change. The Company specifically disclaims any obligation to update the forward-looking information in the future. Therefore, this forward-looking information should not be relied upon as representing the Company’s estimates of its future financial performance as of any date subsequent to the date of this press release. Actual results of our operations may differ materially from information contained in the forward-looking statements as a result of the risk factors.

For further information, please contact:

In China:

Maggie Huang
Investor Relations Manager
Phone: +86-10-6852-2612
Email: fuweiIR@fuweifilms.com

In the U.S.:
Leslie Wolf-Creutzfeldt
Investor Relations
Graying
Tel: +1-646-284-9472
Email: leslie.wolf-creutzfeldt@us.grayling.com

Key Tronic Corp. (KTCC) Announces Increased Second Quarter Guidance

Dec. 2, 2009 (Business Wire) — Key Tronic Corporation (Nasdaq: KTCC), a provider of electronic manufacturing services (EMS), today announced revised guidance for the quarter ending December 26, 2009.

For the second quarter of fiscal 2010, Key Tronic expects to report total revenue in the range of $42 million to $44 million, up from previous estimates of $38 million to $43 million.

The higher than anticipated revenue is expected to result in improved factory utilization and manufacturing efficiencies. As a result, net income for the second quarter of fiscal 2010 is expected to be in the range of $0.10 to $0.13 per share, up significantly from the previous estimate of $0.02 to $0.05 per share.

“Based on preliminary results for the quarter to date and forecasts for the remainder of the second quarter of fiscal 2010, we are seeing stronger than anticipated demand from many of our customers in a wide variety of industries, including our new customer programs which are ramping up faster than projected,” said Craig Gates, President and Chief Executive Officer. “The significant increase in earnings guidance reflects both our stronger than expected revenue and our sustained efforts to enhance our operating efficiency.”

The Company expects to report its complete results for the second quarter of fiscal 2010 on January 26, 2010.

About Key Tronic

Key Tronic is a leading contract manufacturer offering value-added design and manufacturing services from its facilities in the United States, Mexico and China. The Company provides its customers full engineering services, materials management, worldwide manufacturing facilities, assembly services, in-house testing, and worldwide distribution. Its customers include some of the world’s leading original equipment manufacturers. For more information about Key Tronic visit: www.keytronic.com.

Some of the statements in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all passages containing verbs such as ‘aims, anticipates, believes, estimates, expects, hopes, intends, plans, predicts, projects or targets’ or nouns corresponding to such verbs. Forward-looking statements also include other passages that are primarily relevant to expected future events or that can only be fully evaluated by events that will occur in the future. Forward-looking statements in this release include, without limitation, the Company’s statements regarding its expectations with respect to quarterly revenue and earnings during fiscal 2010. There are many factors, risks and uncertainties that could cause actual results to differ materially from those predicted or projected in forward-looking statements, including but not limited to the future of the global economic environment and its impact on our customers and suppliers, the accuracy of customers’ forecasts; success of customers’ programs; timing of new programs; success of new-product introductions; acquisitions or divestitures of operations or facilities; technology advances; changes in pricing policies by the Company, its competitors, customers or suppliers; and the other risks and uncertainties detailed from time to time in the Company’s SEC filings.

Keryx (KERX) Receives FDA Fast Track Designation for KRX-0401 (Perifosine) for the Treatment of Relapsed/Refractory Multiple Myeloma

NEW YORK, Dec. 2 /PRNewswire-FirstCall/ — Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for KRX-0401 (perifosine), the Company’s novel, potentially first-in-class, oral anti-cancer agent that inhibits the phosphoinositide 3-kinase (PI3K)/Akt pathway, for the treatment of relapsed/refractory multiple myeloma.

The Fast Track program of the FDA is designed to facilitate the development and expedite the review of new drugs that are intended to treat serious or life-threatening conditions and that demonstrate the potential to address unmet medical needs. Fast Track designated drugs ordinarily qualify for priority review, thereby expediting the FDA review process.

A Phase 3 trial investigating perifosine in combination with bortezomib (VELCADE®) and dexamethasone for the treatment of patients with relapsed/refractory multiple myeloma is expected to commence by year-end under a Special Protocol Assessment (SPA) with the FDA. In addition, in September, the Company announced that perifosine had received Orphan-Drug designation in the United States for the treatment of multiple myeloma.

Ron Bentsur, Chief Executive Officer of Keryx Biopharmaceuticals, commented, “This Fast Track designation can significantly reduce the FDA review time of a new drug application, and therefore can expedite the time to market for perifosine in multiple myeloma.” Mr. Bentsur added, “We believe that the Fast Track designation, together with the SPA and Orphan Drug status previously granted to us by the FDA for perifosine in multiple myeloma, significantly enhances the value proposition of perifosine in this indication. We are eager to begin the Phase 3 trial later this month.”

KRX-0401 (perifosine) is in-licensed by Keryx from Aeterna Zentaris, Inc. (Nasdaq: AEZS; TSX: AEZ) in the United States, Canada and Mexico.

About KRX-0401 (Perifosine)

KRX-0401 (perifosine) is a novel, potentially first-in-class, oral anti-cancer agent that modulates Akt, and a number of other key signal transduction pathways, including the JNK and MAPK pathways, all of which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. The effects of perifosine on Akt are of particular interest because of the importance of this pathway in the development of most cancers, with evidence that it is often activated in tumors that are resistant to other forms of anticancer therapy, and the difficulty encountered thus far in the discovery of drugs that will inhibit this pathway without causing excessive toxicity. High levels of activated Akt (pAkt) are seen frequently in many types of cancer and have been correlated with poor prognosis.

About Multiple Myeloma

Multiple myeloma, a cancer of the plasma cell, is an incurable but treatable disease. Multiple myeloma is the second most-common hematologic cancer, representing 1% of all cancer diagnoses and 2% of all cancer deaths. According to the American Cancer Society, in 2009 there will be an estimated 20,580 new cases of multiple myeloma and an estimated 10,500 deaths from multiple myeloma in the United States. To date, several FDA approved therapies exist for the treatment of multiple myeloma. Despite this progress, patients continue to relapse, become refractory to prior treatments and eventually die from their disease. Thus, new therapies are needed to treat these patients and extend their survival.

About Keryx Biopharmaceuticals, Inc.

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of life-threatening diseases, including cancer and renal disease. Keryx is developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that inhibits the phosphoinositide 3-kinase (PI3K)/Akt pathway, a key signaling cascade that has been shown to induce cell growth and cell transformation. KRX-0401 has demonstrated both safety and clinical efficacy in several tumor types, both as a single agent and in combination with novel therapies. KRX-0401 also modulates a number of other key signal transduction pathways, including the JNK and MAPK pathways, which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 is currently in Phase 2 clinical development for multiple tumor types, with a Phase 3 in multiple myeloma, under Special Protocol Assessment (SPA), pending commencement by year-end. Keryx is also developing Zerenex(TM) (ferric citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Zerenex has recently completed a Phase 2 clinical program as a treatment for hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease, and Keryx is in the process of finalizing the U.S. Phase 3 program for Zerenex in consultation with the FDA. Keryx is headquartered in New York City.

Cautionary Statement

Some of the statements included in this press release, particularly those anticipating future clinical trials and business prospects for KRX-0401, may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: our ability to successfully and cost-effectively complete clinical trials for KRX-0401; the risk that the data (both safety and efficacy) from the Phase 3 trial will not coincide with the data analyses from the Phase 1 / 2 clinical trial previously reported by the Company; the risk that fast track designation and priority review may not result in earlier approval; and other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at http://www.keryx.com. The information found on our website is not incorporated by reference into this press release and is included for reference purposes only.

Real Goods Solar (RSOL) to Install Low Cost Solar Energy at Bay Area Affordable Housing Communities

Dec. 2, 2009 (Business Wire) — Real Goods Solar announced today it has signed a large multi-site contract to design and install 790 kW DC of solar electricity across four separate affordable housing communities: three in San Francisco and one in Richmond, CA.

The PV systems will be financed through a Power Purchase Agreement (PPA), enabling these properties to use solar-generated power without the upfront capital costs or operational expenses. Upfront installation costs have been significantly reduced by San Francisco Mayor Gavin Newsom’s GoSolarSF solar energy incentive program, and the California Solar Initiative Multi-Family Affordable Solar Housing (MASH) Rebate Program.

This multi-million dollar investment is expected to generate 1,090,311 kWhrs (1.1 MWhrs) of electricity for the residents of these communities, ensuring lower electricity rates for years to come. California’s new Virtual Net Metering tariff will allow the electricity and cost savings to be shared among the resident families as well as the common areas, a first for California.

“This project provides us the opportunity to showcase our strengths at Real Goods Solar, from expert installation to education to renewable energy living,” said John Schaeffer, Founder and President of Real Goods Solar. “Richmond and San Francisco will have beautiful systems that will produce low-cost power for decades to come, and allow them to be an example for sustainability and green collar jobs in the community.”

Through the San Francisco City Build and Solar Richmond workforce training programs, approximately 36 workers who were previously unemployed now have jobs installing the systems.

About Real Goods Solar

Real Goods Solar is a leading solar energy integrator, having installed over 5,000 solar electric systems for both residential and commercial properties. Real Goods Solar offers turnkey solar energy solutions, and has 30 years of experience in solar energy, beginning with its sale of the first solar photovoltaic panels in the United States in 1978. With offices in San Rafael, Richmond, Campbell, Fresno, Santa Cruz, Murrieta, and Hopland, California, as well as in Boulder, Colorado, Real Goods Solar is one of the largest residential solar installers in the United States. For more information, go to www.realgoodssolar.com or call 1-888-507-2561.

Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=6111636&lang=en

Seasoned Clinical Development Expert Joins Opexa (OPXA) to Lead Tovaxin(R) Development in Multiple Sclerosis

Dec. 2, 2009 (Business Wire) — Opexa Therapeutics, Inc. (NASDAQ:OPXA), a company developing a novel T-cell therapy for multiple sclerosis (MS), today announced that Jaye Thompson, Ph.D. has been hired to lead the Company’s efforts to further the clinical development of Tovaxin^®, Opexa’s flagship therapy for MS. Additionally, Dawn McGuire, M.D., Opexa’s expert clinical advisor and member of the Company’s Clinical Advisory Board has agreed to further increase her advisory role in the Company and to represent Opexa as its acting Chief Medical Officer.

Jaye Thompson adds considerable strength to Opexa’s management team as the Senior Vice President of Clinical Development and Regulatory Affairs. Dr. Thompson has significant experience in clinical development having been the president and founder of SYNERGOS, Inc., a full service contract research organization which she managed and successfully grew until its acquisition by inVentiv Health (NASDAQ:VTIV) in 2006. She has advised a number of leading life science companies on strategic and regulatory planning as well as clinical product development. She has directed and managed statistical analysis, data management, report writing and the conduct of clinical trials for a wide variety of indications including MS. Dr. Thompson has been actively involved in over 200 clinical trials for drugs and has been associated with numerous FDA regulatory submissions. Dr. Thompson has a Bachelor’s degree in Applied Mathematics and a Ph.D. in Biostatistics.

“It is a tremendous pleasure joining Opexa at this stage of its development as we prepare for the next clinical milestone for Tovaxin,” stated Dr. Thompson. “There is much potential in Tovaxin and its safety and efficacy are apparent at a time when there is a pressing need for new therapies in this area. I am pleased to be leading the clinical development efforts for Opexa and we have a focused effort within the Company to advance toward the next clinical study with Tovaxin. The first set of priorities is advancing the clinical development program, progressing discussions with the regulatory agencies and supporting our on-going partnering discussions and I look forward to working with Opexa’s already strong management team to deliver on these targets.”

Dr. McGuire, who has been advising Opexa as a consultant and who has substantial expertise in the clinical management of MS, is also strengthening her role with the Company. She is a board certified neurologist and served as development leader of Tysabri^® as Vice President of Clinical Research and Medical Affairs at Elan Pharmaceuticals. Dr. McGuire has agreed to deepen her involvement with the Company as its acting Chief Medical Officer and will work closely with Dr. Thompson to guide the Company’s efforts to further the clinical development of Tovaxin.

“I am pleased to increase my role in helping advance Tovaxin effectively through clinical development,” commented Dr. McGuire. “The analysis of the Phase IIb data has been very encouraging, and safety and efficacy data strongly support the continued development of Tovaxin. Roughly half of MS patients are not on any therapy, and Tovaxin has the potential to be a compelling treatment option across patient groups, including the newly diagnosed. Early data suggest that Tovaxin may be neuroprotective, as indicated radiographically by reduction in brain atrophy and clinically by stability or improvement in disability. Among patients with frequent MS exacerbations, Tovaxin appears to reduce the relapse rate substantially. I look forward to working with Dr. Thompson and the entire Opexa team in their efforts to advance Tovaxin through clinical development.”

“I couldn’t be more pleased with the clinical team that is now in place to move Tovaxin forward,” commented Neil K. Warma, Opexa’s President and CEO. “The combination of Jaye’s substantial hands-on experience in clinical development and regulatory affairs and Dawn’s MS drug development expertise positions us very well to advance the clinical development of Tovaxin. Finalizing the clinical development plan will continue in parallel with on-going partnering discussions. We had a constructive third quarter marked not only by the TERMS data analysis of Tovaxin efficacy, but also by the stem cell agreement with Novartis, which booked revenue for the first time in Opexa’s history and strengthened the Company’s balance sheet. This has allowed us to remain focused on Tovaxin and to assemble a world-class management team. We are making clear progress in our efforts to bring one of the more promising MS treatments to the patients in need.”

About Opexa

Opexa Therapeutics, Inc. is dedicated to the development of patient-specific cellular therapies for the treatment of autoimmune diseases. The Company’s leading therapy, Tovaxin^®, is an individualized cellular immunotherapy treatment in Phase IIb clinical development for Multiple Sclerosis (MS). Tovaxin is derived from T-cells isolated from peripheral blood, expanded ex vivo, and reintroduced into the patients via subcutaneous injections. This process triggers a potent immune response against specific subsets of autoreactive T-cells known to attack myelin, believed to be a primary cause of MS attacks and nervous system damage.

For more information visit the Opexa Therapeutics website at www.opexatherapeutics.com.

Cautionary Statement Relating to Forward – Looking Information for the Purpose of “Safe Harbor” Provisions of the Private Securities Litigation Reform Act of 1995

This press release contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements in this release do not constitute guarantees of future performance. Investors are cautioned that statements in this press release which are not strictly historical statements, including, without limitation, statements regarding current or future financial payments, returns, royalties, performance and position, management’s strategy, plans and objectives for future operations, plans and objectives for product development, plans and objectives for present and future clinical trials and results of such trials, plans and objectives for regulatory approval, litigation, intellectual property, product development, manufacturing plans and performance, and management’s initiatives and strategies, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including, without limitation, risks associated with: the success of third party development and commercialization efforts with respect to products covered by intellectual property rights transferred by the Company, the success of third party patent prosecution efforts with respect to such products, the ability of the Company to enter into and benefit from a partnering arrangement for the Company’s product candidate, Tovaxin, on reasonably satisfactory terms (if at all), and our dependence (if partnered) on the resources and abilities of any partner for the further development of Tovaxin, our ability to compete with larger, better financed pharmaceutical and biotechnology companies, new approaches to the treatment of our targeted diseases, our expectation of incurring continued losses, our uncertainty of developing a marketable product, our ability to raise additional capital to continue our treatment development programs, the success of our clinical trials, our ability to develop and commercialize products, our ability to obtain required regulatory approvals, our compliance with all Food and Drug Administration regulations, our ability to obtain, maintain and protect intellectual property rights for our products, the risk of litigation regarding our intellectual property rights, our limited manufacturing capabilities, our dependence on third-party manufacturers and value added resellers, our ability to hire and retain skilled personnel, our volatile stock price, and other risks detailed in our filings with the Securities and Exchange Commission. We assume no obligation to update any forward-looking information contained in this press release or with respect to the announcements described herein.

Enova Systems (ENA) and Freightliner Custom Chassis Corporation on Target to Deploy All-Electric Fleets

Dec. 1, 2009 (Business Wire) — Enova Systems, Inc., (NYSE AMEX:ENA) (AIM:ENV) (AIM:ENVS) a leading developer of propriety electric, hybrid and fuel cell digital power-management systems propelling the alternative energy industry, announces the company has completed a major step toward greening North America’s commercial fleets.

In a four-phase initiative launched in collaboration with Freightliner Custom Chassis Corporation (FCCC), the companies plan to deliver all-electric commercial vehicles to the North American fleet market by 2010. Today they announce the completion of the ambitious program’s first phase.

“We are on target with FCCC to achieve our shared goal of deploying all-electric vehicles with national fleets in early 2010,” says Enova Chief Operating Officer, John Mullins. “This is welcome news for the many fleets and parcel delivery companies across North America that are looking to transition to all-electric vehicles in 2010.”

To support this transition, Enova is integrating its 120kW all-electric drive system technology with strategically selected FCCC chassis platforms, including the MT-45 walk-in van chassis used by a range of FCCC’s national fleet customers. The company’s highest volume chassis, the MT-45 offers a gross vehicle weight up to 19,000 lbs. with maximum payloads of 10,000 lbs.

“As part of the first phase of our joint initiative, we demonstrated the Enova Ze walk-in van powered by our integrated all-electric drive technology to key customers and national fleet industry decisions-makers,” explains Mullins. “The response has been extremely enthusiastic.”

Among those who participated in the demonstrations were the U.S. Department of Energy, United States Postal Service, US Postal Regulatory Commission, and the New York State Energy Research and Development Authority (NYSERDA). During 2009 Enova also demonstrated the all-electric Ze van at conferences across the nation, including the Plug-In 2009 Conference in Long Beach, CA; the NC and SC Clean Cities Coalition in Gaffney, SC; and the Calstart Hybrid Truck Users Forum Conference in Atlanta, GA.

In 2009, Enova and FCCC identified and qualified national fleet operators who will receive the first deployment of pilot vehicles. Enova also completed a supplier audit conducted at the company’s Torrance facility.

“With the completion of our first phase, Enova and FCCC are gearing up for the next phase,” says Mullins. “We’re preparing to demonstrate the outstanding performance of our electric vehicles on real-world delivery routes, and deploy EVs across the commercial fleet segment. 2010 is poised to be a green year for national fleets.”

About Freightliner Custom Chassis

Freightliner Custom Chassis Corporation manufactures premium chassis for the motor-home, delivery walk-in van, and school bus and shuttle bus markets. Freightliner Custom Chassis Corporation is a subsidiary of Daimler Trucks North America LLC, a Daimler company. For more information, visit www.freightlinerchassis.com.

About Enova

Enova Systems (NYSE AMEX:ENA) (AIM:ENV) (AIM:ENVS) is a leading supplier of efficient, environmentally friendly digital power components and systems products. The Company’s core competencies are focused on the development and commercialization of power management and conversion systems for mobile applications. Enova applies unique “enabling technologies” in the areas of alternative energy propulsion systems for light and heavy-duty vehicles as well as power conditioning and management systems for distributed generation systems. The Company develops, designs and produces non-invasive drive systems and related components for electric, hybrid-electric, and fuel cell powered vehicles in both the “new” and “retrofit” vehicle sales market. For further information, contact Enova Systems directly, or visit www.enovasystems.com.

Tianyin Pharmaceutical Co., Inc. (TPI) Receives Chinese SFDA New Product Approvals for 2 Generic Products

CHENGDU, China, Dec. 1, 2009 (PRNewswire-Asia-FirstCall) — Tianyin Pharmaceutical Co., Inc., (NYSE Amex: TPI), a manufacturer and supplier of modernized traditional Chinese medicine (“TCM”) based in Chengdu, China, today announced that it has received approvals from the Chinese State Food and Drug Administration (SFDA) to produce Pediatric Fever and Cough Oral Liquid in dosage form of 10 ml/tube (SFDA approval number Z20093060) and Antibacterial and Anti-inflammatory Capsules in dosage form of 0.27 gram/capsule (SFDA approval number Z20090855).

Pediatric Fever and Cough Oral Liquid is a generic prescription TCM that is used for respiratory tract infections and influenza of children to effectively reduce symptoms such as fever, shakes, cough, phlem, shortness of breath, dry mouth and sore throat. According to Tianyin’s market research and estimation, annual sales of this type of products are approximately $1.1 billion in China. Tianyin expects the demand of this product will increase during the wintertime flu season and that our introduction of this product will increase the Company’s market share in the pediatric medicine market.

Antibacterial and Anti-inflammatory Capsules is a generic OTC TCM which is used mainly as natural antibiotics to treat bacterial infection and inflammation. It has minimal side effects when compared to western antibiotics. Tianyin estimates that total annual sales of antibacterial and anti-inflammatory products are approximately $1.5 billion in China. Tianyin expects to gain a portion of the market share in antibiotics medicine through the production and marketing of Antibacterial and Anti-inflammatory Capsules. The product will be manufactured in Company’s new production facility.

“We are very pleased to receive approvals for our Pediatric Fever and Cough Oral Liquid and Antibacterial and Anti-inflammatory Capsules from the Chinese SFDA. One of our key growth strategies is to further expand our portfolio,” Dr. Guoqing Jiang, Chairman and CEO of Tianyin Pharmaceutical Co., Inc., commented. “These products further complement our product portfolio and create additional revenue opportunities for indications which we have not previously addressed. We will immediately leverage current distribution network and available production capacity to produce these two products.”

About Tianyin Pharmaceuticals

Tianyin is a manufacturer and supplier of modernized Traditional Chinese Medicine (“TCM”) in China. It was established in 1994 and acquired by the current management team in August 2003. It has a comprehensive product portfolio of 39 products, 22 of which are listed in the highly selective National Medicine Catalog of the National Medical Insurance program. Tianyin owns and operates two GMP manufacturing facilities and an R&D platform supported by leading Chinese academic institutions. The Company has a pipeline of 17 pharmaceutical products pending approval. Tianyin has an extensive nationwide distribution network throughout China with a sales force of 720 salespeople. Tianyin is headquartered in Chengdu, Sichuan Province with two manufacturing facilities and a total of 1,365 employees. For more information about Tianyin, please visit http://www.tianyinpharma.com .

Safe Harbor Statement

The Statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company’s filings with the Securities and Exchange Commission.

Alexco Resource Corp. (AXU) Announces Additional 2009 Drill Results, Keno Hill District, Yukon

VANCOUVER, BRITISH COLUMBIA — (Marketwire) — 12/01/09 — Alexco Resource Corp. (TSX: AXR)(NYSE Amex: AXU) (“Alexco” or the “Company”) is pleased to announce additional results from its 2009 exploration core drilling program at the Keno Hill Project, Yukon. Exploration drilling on the #5 vein system, one of several vein systems occurring in the vicinity of the historical Silver King mine, has intersected silver-rich mineralization approximately 160 meters northeast of previous Alexco drilling in 2006 and 2007.

Silver King Drill Results

– Assay results have been received for a single core hole drilled on the Silver King #5 vein, one of several veins within the historical Silver King mine area. Results are as follows:

— DDH K09-218 cut an interval grading: 1,932 grams per tonne silver (56.4 ounces per ton), 11.3% lead and 0.4% zinc over 2.55 meters from 201.85 to 204.40 within a 7.65 meter interval grading 679 grams per tonne silver (19.8 ounces per ton), 3.9% lead and 0.2% zinc from 201.85 to 209.50 meters.

The 2009 drill hole intersected the Silver King #5 vein lower in the geologic section than previously tested, encountering significant mineralization which remains open both along strike to the northeast and down dip to the southeast. The majority of the historical Silver King resource, described below, is present within the #5 vein system which is also well accessed by historical underground development.

Silver King Historical Production, Historical Resource, Mineralization

The Silver King mine, with historical production of approximately 11 million ounces of silver at an average grade of 53 ounces per ton silver, was the site of the initial silver discovery in the Keno Hill area. A remaining resource estimate for the area encompassing the existing underground workings at Silver King was calculated by the previous property owner’s staff in the 1990’s. This historical resource estimate, including proven, probable and inferred mineralization, totaled 134,018 tons grading 40.05 ounces per ton silver, 1.33% lead and 0.14% zinc. Although believed to be relevant and reliable by Alexco management, this historical resource predates National Instrument 43-101 (“NI 43-101”) and is not compliant with NI 43-101 resource categories.

Historical mineralization in the Silver King area is hosted in multiple, intersecting northeast-trending and east-trending veins and stockworks occurring over a strike length of approximately 2 kilometers. Two major vein systems, the #1 (northeast-trending) and the #2 (east-trending), intersect near Galena Creek, the site of the original Silver King discovery workings. The bulk of the Silver King production came from these two veins, where they intersect favorable stratigraphy, quartzite-rich units adjacent to schistose interbeds.

Prior Alexco drilling at Silver King mainly targeted the #1 vein system while passing through the upper part of the #5 vein where it occurs in schist-rich rocks overlying quartzite-rich units. This earlier drilling intersected mineralization grading up to 93.6 ounces per ton silver over 1.0 meters (see news release dated November 2, 2006 entitled “Alexco Announces Initial Keno Hill Drill Results”) and 307.3 ounces per ton silver over 0.8 meters (see news release dated September 18, 2007 entitled “Alexco Announces Additional 2007 Keno Hill Drill Results”) with both intercepts occurring in quartzitic members of the schist-rich upper unit. This part of the #5 vein system was also explored by historical underground workings and drilling but with limited exploration in the favorable lower quartzites. Drill hole K09-218 intersected the #5 vein in lower quartzite-rich rocks approximately 160 meters northeast (along strike) and 143 meters southeast (down dip) from previous Alexco drilling in 2006 and 2007.

Alexco plans to aggressively explore the Silver King area in 2010 focusing on the #5 vein and other select mineralized Silver King structures, specifically where those structures project into more favorable quartzite-rich rocks.

Future Exploration

Due to the tenor of the Silver King intercepts drilled by Alexco, the exploration potential on multiple vein systems and the presence of an historical resource of significant grade, Alexco has selected the Silver King area as a target for short term definition drilling and possible development. With the high grade Bellekeno silver mine now under construction, based on results from the 2009 exploration program Alexco anticipates that the next resources to be evaluated for possible development and production in the Keno Hill Silver District will include the historical Silver King mine, the new discoveries at Lucky Queen (see news release dated November 9, 2009 entitled “Alexco Announces Additional 2009 Drill Results from Lucky Queen, Keno Hill District: Drilling Intersects 4.23 Meters of 61.8 Ounces per Ton Silver”) and the former Onek mine (see news release dated July 2, 2008 entitled “Alexco Announces Initial 2008 Drill Results at Keno Hill: Exploration and Infill Drilling at Onek Prospect Confirms Zinc-Silver Mineralization”).

All of the released 2009 Keno Hill drillhole results are available on the Alexco website at www.alexcoresource.com. Plans/sections for the areas drilled showing locations of the completed drill holes are also available for review.

Notes

True widths have not been determined for all the above reported drill intercepts but are believed to be representative of actual drill thicknesses.

The 2009 exploration drill program and sampling protocol has been reviewed, verified and compiled by Alexco’s geologic staff under the oversight of Stan Dodd, Vice President, Exploration for Alexco and a Qualified Person as defined by NI 43-101. A rigorous quality control and quality assurance protocol is used on the project, including blank, duplicate and standard reference samples in each batch of 20 samples that were delivered to the lab. All drill core samples were shipped to Eco Tech Laboratory at Whitehorse, YT for preparation with fire assay and multi-element ICP analyses done at Eco Tech Laboratory’s facility at Kamloops, BC.

Keno Hill Silver District History

Between 1921 and 1988, the Keno Hill Silver District produced more than 217 million ounces of silver with average grades of 40.5 ounces per ton silver, 5.6% lead and 3.1% zinc (Yukon Government’s Minfile database). The historical production grades would rank Keno Hill in the top 3% by grade of today’s global silver producers. The Keno Hill district is the second-largest historical silver producer in Canada.

About Alexco

Alexco’s business is to unlock value and manage risk at mature, closed or abandoned mine sites through integration and implementation of the Company’s core competencies which include management of environmental services, execution of mine reclamation and closure operations and if appropriate, rejuvenation of exploration and development of new mining opportunities.

Some statements in this press release contain forward-looking information. These statements include, but are not limited to, statements with respect to the entering into of agreements, the closing of transactions and the expenditure of funds. These statements address future events and conditions and, as such, involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the statements. Such factors include, among others, the timing of transactions, the ability to fulfill certain conditions, the ability to raise funds and the timing and amount of expenditures.

Zion Oil & Gas (ZN) – $18 Million Rights Offering Oversubscribed

DALLAS and CAESAREA, Israel, Dec. 1, 2009 (GLOBE NEWSWIRE) — Zion Oil & Gas, Inc. (Nasdaq:ZN) announced today the preliminary results of its rights offering to stockholders, offering 3.6 million shares of Zion’s common stock at a subscription price of $5.00 per share. The rights offering terminated yesterday, November 30, 2009, as originally scheduled. Preliminary results indicate that subscriptions were received for over $37 million, significantly greater than the maximum available of $18 million.

The total available subscription of 3.6 million shares, for gross proceeds of $18 million, will be accepted by Zion and amounts for the unfilled oversubscriptions will be refunded as soon as possible. As detailed in the prospectus, oversubscription rights will be allocated pro rata in accordance with the number of basic subscriptions rights exercised.

Zion’s Chief Executive Officer, Richard Rinberg, said today, “I am pleased to announce the successful conclusion of our rights offering. The significant oversubscription is very gratifying and shows the high level of interest in our oil and gas exploration work in Israel. The $18 Million proceeds will provide us with financial and operating flexibility and will enable us to significantly further our exploration and drilling program.”

Under the completed rights offering, holders of record of Zion’s common stock, as of the close of business on October 19, 2009, were given non-transferable subscription rights to purchase up to 3.6 million shares of common stock at a subscription price of $5.00 per share.

Zion is currently drilling its Elijah #3 well and drilling has reached a depth of approximately 5,250 feet (1,600 meters). Next week, Zion plans to carry out completion testing on its Ma’anit-Rehoboth #2 well that was drilled to a depth of 17,913 feet (5,460 meters).

For updates on the drilling activity please visit Zion’s website “www.zionoil.com”.

Zion Oil & Gas, a Delaware corporation, explores for oil and gas in Israel in areas located on-shore between Haifa and Tel Aviv. It currently holds two petroleum exploration licenses, the Joseph and the Asher-Menashe Licenses, between Netanya in the south and Haifa in the north, covering a total of approximately 162,000 acres and the Issachar-Zebulun Permit Area, adjacent to and to the east of Zion’s Asher-Menashe license area, covering approximately 165,000 acres. Zion’s total petroleum exploration rights area is approximately 327,000 acres.

Zion’s common stock trades on the NASDAQ Global Market exchange under the symbol “ZN” and Zion’s warrants trade under the symbol “ZNWAW”.

The Zion Oil & Gas, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=6850

FORWARD-LOOKING STATEMENTS: Statements in this press release that are not historical fact, including statements regarding Zion’s operations and planned operations are forward-looking statements as defined in the “Safe Harbor” provision of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on assumptions that are subject to significant known and unknown risks, uncertainties and other unpredictable factors, many of which are described in Zion’s periodic reports filed with the SEC and are beyond Zion’s control. These risks could cause Zion’s actual performance to differ materially from the results predicted by these forward-looking statements. Zion can give no assurance that the expectations reflected in these statements will prove to be correct and assumes no responsibility to update these statements.